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INTRODUCTION 
When congenital diaphragmatic hernia (CDH) was first described in the early 18th 
century, it was considered as a result of an opening in the diaphragm that theoretically 
could be easily corrected after birth by removal of the herniated viscera and subsequent 
closure of the diaphragm. Over the past three decades, however, it has become evident 
that CDH is an anomaly characterized by not only a diaphragmatic defect, but also a 
variable amount of pulmonary hypoplasia (PH) and lung immaturity in some cases. Apart 
from these features, pulmonary vascular abnormalities may occur and cause persistent 
pulmonary hypertension of newborn (PPHN).1,2 
 
Hypoplastic lungs are characterized by fewer airways and smaller air spaces, and thus 
the lower number of vascular generations and increased adventitia and medial thickness 
of pulmonary arterial walls give rise to pulmonary hypertension.1,2 Apart from the 
morphologic abnormalities in the pulmonary vasculature, an alternate expression of 
various cellular mediators, such as nitric oxide, endothelin, prostaglandins, 
catecholamines, and renin-angiotensin system, have been suggested to contribute to the 
pathogenesis of PPHN in CDH patients.3,4 
  
Classically, CDH is considered as a primary defect of diaphragmatic embryogenesis 
resulting from failure of formation or fusion of pleuroperitoneal membranes. 
Consequently, the abdominal organs herniate into the ipsilateral thoracic cavity when the 
midgut returns to the abdominal cavity around the 10th gestational week. The timing of 
herniation coincides with the critical period of lung development and in utero competition 
for space of the developing lung and the 'abdominal viscera' leads to pulmonary 
hypoplasia.5 However, more recent experimental evidence suggests that lung hypoplasia 
may occur independently as a result of defects in signaling pathways.6 Recently the 
retinoid hypothesis has gained much interest – reviewed by Clugston et al.7 – and also  
we have gained much greater understanding of the role of specific genes in the etiology 
of CDH.8 Different animal models have been used to study the natural history of CDH, 
but current understanding of its etiology and pathophysiology remains limited.  
 
 
EPIDEMIOLOGY AND CLINICAL ASPECTS OF CDH 
The incidence of CDH is approximately one in 2500 live births.9 The typical form is the 
posterolateral or so-called Bochdalek hernia (95%), of which 85% occur on the left 
side.10 With 2% or less incidence, familial cases are sporadic.6 A number of 
chromosomal anomalies have been described in CDH cases, including trisomy 13, 
trisomy 18 and tetrasomy 12P, but no single gene mutation has been identified.11  In 
some 40 to 50% of CDH cases, associated anatomical anomalies occur, with heart and 
limbs defects being the most frequent.10,12  
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Despite advancements in neonatal intensive care and ventilation, including inhaled nitric 
oxide, high frequency oscillatory ventilation and extracorporeal membrane oxygenation 
(ECMO) in selected infants, both morbidity and mortality in infants with CDH remain 
high.13 Hidden mortalities (in utero death, termination of pregnancy) underscore the true 
outcome in population-based surveys.14-16 Major factors limiting survival of infants with 
CDH are pulmonary hypoplasia and PPHN.  
 
As numbers of patients even in 'high volume' centers is relatively low (15 - 20 per year) 
the individual treatment of a new patient with CDH should still be considered a matter of 
trial and error. Therapies proven to be effective in randomized controlled trials are not 
available. 
 
As such case selection is the major determinant of outcome and depends on: 
- pre/postnatal diagnosis 
- inborn – outborn 
- ECMO facility yes/no 
- Inclusion of long-term follow-up or evaluation at hospital discharge, etc. 
 
 
PRENATAL DIAGNOSIS 
The increased use of prenatal ultrasound allows antenatal diagnosis of CDH. The 
diaphragm can be visualized as early as in the first trimester. Its absence is indirectly 
evident by the presence of abdominal organs in the thoracic cavity and displacement of 
thoracic organs.17 A European study reports around 60% antenatal diagnosis of CDH, at 
a mean gestational age of 24 weeks.18 Prenatal diagnosis has raised the issue of 
predicting survival and outcome. Many different criteria have been proposed for prenatal 
imaging. Lung-to-head ratio, evidence of liver herniation or associated anomalies are 
widely used as prognostic factors,17,19 although still under debate.20 There is still no 
consensus, however, on the ideal determinant of postnatal outcome in infants with CDH. 
It would seem imperative to develop standardized prenatal criteria for prediction of 
postnatal outcome that allow accurate and thorough prenatal counseling and planning of 
treatment. 
 
 
POSTNATAL MANAGEMENT 
Basic approach 
The philosophy of postnatal care has changed with the progress in understanding the 
pathophysiology of CDH. Until the 1980s, it was believed that an emergency surgical 
procedure aimed at reducing the herniated abdominal viscera could improve hypoxia and 
hypercarbia in infant with CDH. Since then, however, delayed surgery following 
stabilization has become the widely accepted approach to manage CDH patients 
resulting in case selection for surgical correction. Many therapeutic strategies are used 
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with the aim to reduce hypoxia, ventilator associated lung injury and pulmonary 
hypertension, and right-to-left shunting. High-frequency oscillatory ventilation (HFOV) is 
used to increase tissue oxygenation whilst minimizing volutrauma to the lung. Although 
not yet evaluated in randomized controlled trials, ECMO has been accepted as a method 
for treatment of infants with respiratory failure refractory to all other ventilatory and 
supportive therapies. However, HFOV and ECMO show no clear benefit over 
conventional respiratory care in CDH patients.21-25 Today clinicians are aware that the 
different ventilatory regimens have deleterious effects on the hypoplastic lung. More 
centers now advocate prevention of ventilator-induced lung injury by using the 'gentle 
ventilation' concept of permissive hypercapnia, spontaneous respiration and avoidance 
of hyperventilation and barotraumas in CDH infants.24-26 Exogenous surfactant therapy is 
widely used to improve oxygenation in premature infants but observational data from the 
International CDH Registry do not confirm any benefit of this therapy, neither in preterm 
nor in term born infants with CDH.27,28 Today no data are available showing a primary 
surfactant deficiency in newborns with CDH.29 
 
 
IN UTERO MANAGEMENT OF CDH, THE ULTIMATE SOLUTION? 
While advances in neonatal care have to some extent improved the survival of infants 
with CDH, morbidity still remains significant, for example in the form of chronic oxygen 
dependency, gastroesophageal reflux, poor growth and developmental delay. The 
evolution of prenatal diagnosis offers a possibility for prenatal interventions in an attempt 
to promote lung growth before birth and consequently to improve the prognosis. 
 
Fetal surgical interventions 
Primary prenatal repair was unsuccessful in most of the severe cases (those with liver 
herniation) because reduction of the liver back into the abdomen caused obstruction of 
umbilical venous blood flow, leading to bradycardia and fetal death. Although this 
procedure is technically feasible, a randomized controlled trial in fetuses without liver 
herniation did not show a significant benefit over conventional postnatal care.30 In view of 
this finding, efforts then were focused directly on treating pulmonary hypoplasia.  
 
The observation that infants with laryngeal atresia develop enlarged hyperplastic lungs 
forms the basis for the PLUG approach: Plug the Lung Until it Grows.31 Fetal tracheal 
ligation in CDH results in tremendous lung growth, reversal of pulmonary hypoplasia but 
fewer type II pneumocytes and lower alveolar phospholopid content.32,33 A randomized 
controlled trial sponsored by the US National Institutes of Health (NIH) reported that fetal 
endoscopic tracheal occlusion failed to improve survival or morbidity rate of the fetuses 
with CDH compared with standard postnatal care.34 To date the trials continue in Europe 
using temporary fetoscopic endoluminal tracheal occlusion with refined techniques and 
inclusion criteria,17 in selected 'liver-up' cases without associated anatomical or 
chromosomal abnormalities. At present over 40 fetuses have been evaluated and 
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compared with cases with a proven mortality rate of over 80% (Personal communication, 
Deprest, Belgium). 
 
Pharmacological intervention 
Hormonal therapy 
Antenatal glucocorticoid (GC) therapy was proven to accelerate pulmonary maturity and 
is recommended for all pregnancies between 24 and 34 weeks of gestation if premature 
delivery is expected.35 In the Nitrofen-induced CDH rat model, there is evidence that 
antenatal steroids improve lung maturity, reduce saccular septal thickness and increase 
surfactant content.36 However, the evidence of surfactant deficiency and lung immaturity 
in animals and human infants with CDH is controversial.37 Several reports have shown 
normal surfactant levels in rats with Nitrofen-induced CDH as well as in patients.29,37-39 
Despite encouraging result in three CDH cases reported by Ford et al.,40 a recent report 
by the CDH Study Group does not recommend antenatal steroid administration beyond 
34 weeks of pregnancy.41 A planned trial evaluating the standardized use of 
corticosteroids in prenatally diagnosed CDH was never achieved due to the low inclusion 
rate and absence of Institutional Review Board approval in many centers.41 
 
The significant effect of thyroid hormone on lung development was observed in the 
Nitrofen-induced CDH rat model. The combined administration of thyroid hormone (T4) 
and Nitrofen to pregnant rats reduced the number of malformations in the offspring. 
Research of the role of thyroid hormone on lung development has concentrated on the 
later stages of lung development, particularly the regulation of surfactant production.42 
Thyroid hormone seems to act synergistically with glucocorticoid in stimulating surfactant 
release; when used alone, however, it failed to show consistent stimulation effects on 
lung development.43 
 
Vitamin A status 
The first indication of a link between vitamin A deficiency and CDH came from the 
observation of diaphragmatic defect in rat pups born from vitamin A deficient dams as 
early as 1949. Defect rates decreased when vitamin A was supplemented to the diet 
during mid-gestation.44,45 Some offspring of retinoid receptors (RARα/β) null-mutant mice 
have diaphragmatic hernia similar to that observed in Nitrofen-induced CDH rats.46,47 In 
the Nitrofen-induced CDH model, the antenatal administration of vitamin A to pregnant 
dams significantly increased survival rate and lung growth, and simultaneously 
decreased the incidence of CDH in the offspring.48,49 The developing diaphragm strongly 
expresses proteins associated with metabolism and binding of retinoids.50 There is now 
strong evidence that the retinoid signaling pathway is involved at least in the Nitrofen-
induced CDH rat model. Such evidence is lacking in human CDH; only one study 
reported decreased blood parameters of the vitamin A status (i.e. retinol and retinoid 
binding protein) in newborns with CDH compared with healthy newborns.51 Nevertheless, 
retinoids are known to play a crucial role in diaphragm and lung development. Further 
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investigations are needed to assess the potential of prenatal vitamin A and/or derivates 
supplementation on outcome of CDH. 
 
 
CONCLUDING REMARKS AND AIM OF THE STUDIES 
CDH continues to be a challenge for clinicians because many questions remain 
unanswered so far. The variability of phenotypic expression of CDH makes it difficult to 
standardize treatment. Inevitably, treatment strategies have to be adapted to the 
individual patient. The primary goal is to reduce morbidity and mortality. Understanding 
the basic mechanisms of normal and abnormal lung development is mandatory to come 
to evidence-based therapy in CDH. Many researchers have tried to modulate growth and 
differentiation of either or both airways and the vasculature, either by fetal surgical 
interventions or by pharmacological approaches. Obviously, most of the studies are 
based on animal models. Up till now, human data are too limited to permit assessing the 
potential of new therapeutic modalities in human CDH.  
 
In order to add to the human data, the specific aims of the studies described in this thesis 
are as follows: 
1. Are the members of the steroid nuclear receptors superfamily differently 
expressed in normal and CDH human lungs during development and in the 
Nitrofen-induced rat model of CDH? (Chapters 2 & 3) 
2. Are the various angiogenic factors involved in the VHL pathway expressed 
differently during normal human pulmonary development? (Chapter 4) 
3. What is the effect of low oxygen concentration on the angiogenic factors VEGF, 
VEGFR-2, HIFs in human fetal lung explants cultures in vitro? (Chapter 5) 
4. Are there any disturbances in proliferation and apoptosis in CDH human lung 
morphogenesis and normal lungs of different gestational ages? (Chapter 6) 
 
The findings from these studies are discussed in the general discussion (Chapter 7) and 
summarized in Chapter 8. 
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ABSTRACT 
Context 
Although glucocorticoid hormone, thyroid hormone, and retinoic acid play important roles 
in fetal development, the expression of their receptors in human lung is still unknown. 
 
Objective 
The aim of this study was to investigate the ontogeny of glucocorticoid receptor (GR)α, 
thyroid hormone receptors (TRs), retinoic acid receptors (RARs), and retinoid X 
receptors (RXRs) mRNA expression in human lungs. 
 
Design 
Lungs from human fetuses and neonates (13.5 - 41 wk gestation; n = 20) as well as 
adults (n = 5) were analyzed by real-time PCR to monitor the ontogeny of mRNA 
expression for each receptor. In addition, immunohistochemistry was performed to show 
the cellular distribution of the different receptors. 
 
Results 
The expression of GRα, TRs, RARs, and RXRs was already detected in the earliest 
developmental stages analyzed. There was no significant difference in mRNA expression 
between developmental groups for any of the genes studied. However, for fetal and 
neonatal samples, there were positive correlations between gestational age and mRNA 
expression for RARα (r = 0.665; P = 0.001), RXRα (r = 0.444; P = 0.050), and RXRγ 
(r = 0.464; P = 0.039). Immunohistochemical studies showed the presence of GRα, TRs, 
RARs, and RXRs in the nuclei of both epithelial and mesenchymal cells, albeit more 
pronounced in epithelium of larger airways.  
 
Conclusions 
The detection of GRα, TRs, RARs, and RXRs expression in human lung as early as 13.5 
wk gestation implies an early potential for therapeutic or toxic effects by exogenous 
analogs or by excess of endogenous ligands.  
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INTRODUCTION 
In humans, lung development starts around the fourth week of gestation with the 
formation of two endodermally derived lung buds. The main bronchi and segmental 
bronchi are formed through branching morphogenesis, until the bronchial tree is 
completed by wk 16. The lumina of the bronchi and terminal bronchioles become larger, 
and vascularization is more prominent during the canalicular period (17 - 26 wk 
gestation). Further subdivision of bronchioles and formation of primitive alveoli occurs in 
the saccular period (24 - 36 wk gestation until term). In the alveolar period (from 36 wk 
onward), the gas exchange surface of the lung increases due to the thinning of the 
squamous epithelial layer, forming thin-walled alveoli. This alveolization continues after 
birth and is completed in childhood.1-5 
 
Many factors, including hormonal, biochemical, and physical factors, have been identified 
that modulate growth and development of the lungs.4,6-8 Among these, glucocorticoids, 
thyroid hormone, and retinoic acid (RA) are described to influence the growth of lungs. 
Glucocorticoid plays a role in the regulation of surfactant proteins and lipids during lung 
maturation;1,7 therefore, antenatal corticosteroids were recommended by National 
Institutes of Health consensus to all fetuses between 24 and 34 wk gestation at risk of 
preterm delivery.6,9 This will lead to an induction of surfactant production, an acceleration 
of lung maturation, and an increase in lung compliance. Thyroid hormone, independently 
or in conjunction with glucocorticoids, has been implicated in the growth and maturation 
of the perinatal lung. Early reports suggested that thyroid hormone concentrations in cord 
blood of premature infants with respiratory distress syndrome were low, relative to age 
and birth weight-matched controls, but these findings were not supported in later 
studies.10 Vitamin A, and its active metabolite RA, has a role in cellular differentiation via 
binding to its receptors.5,11,12 In animal studies, both the lack and excess of vitamin A 
during embryonic development result in congenital malformations such as infertility, 
anopthalmia, and lung hypoplasia.11,13,14 In humans, lower plasma vitamin A levels were 
found in prematurely born infants, especially in cases with respiratory distress or 
pulmonary hypoplasia associated with congenital diaphragmatic hernia.15,16 
 
The actions of these ligands are mediated through the activation of their receptors, which 
belong to a superfamily of ligand-dependent transcriptional proteins. All members of the 
family share a highly conserved similar modular structure with discrete functional 
domains for hormone binding, DNA binding, and transactivation. Through the DNA 
binding domain, the receptor binds to specific DNA sequences as monomers, 
homodimers, or heterodimers.17,18 Unlike other steroid hormone receptors, glucocorticoid 
receptor (GR)α resides primarily in the cytoplasm of cells in the absence of ligands.19 
Thyroid hormone receptors (TRs) are encoded by two genes (α and β), each producing 
several isoforms, among which TRα1 and TRβs act as functional receptors. Retinoid 
receptors are classified into two subtypes, RA receptors (RARs) and retinoid X receptors 
(RXRs). Each subtype comprises three major isoforms, α, β, and γ. Although 9-cis-RA 
binds to both RARs and RXRs, all-trans-RA binds preferably to RARs.20 Aside from the 
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classical model in which the steroid hormones elicit a transcriptional response upon 
binding to their cognate receptor, there appears to be a nongenomic action described for 
at least the glucocorticoids and the thyroid hormone. This nongenomic response occurs 
rapidly (within minutes) and is unaffected by inhibitors of transcription and protein 
synthesis. The site of the response can be at the plasma membrane, in the cytoplasm, 
and in cellular organelles.21-24 
 
Because the level of nuclear receptor expression determines cell sensitivities to certain 
hormones,25 the presence of these receptors in human lung has been studied previously 
by various techniques.26-29 However, the ontogeny of their expression has not been 
shown in a systematic way before. To elucidate their expression patterns during human 
lung development, we examined the expression of GRα, TRα, TRβ, RARs, and RXRs in 
human lung tissue, from 13.5 wk gestation until term, by real-time PCR and 
immunohistochemistry.  
 
 
MATERIALS AND METHODS 
Tissue samples 
After approval of the University Ethical Committee of the experimental design and 
protocols, lung tissues were retrieved from the archives of the Department of Pathology, 
Erasmus MC, Rotterdam. Fetal and neonatal lung tissues (n = 20) were obtained from 
either elective termination of pregnancy or autopsies. All samples were harvested within 
24 h after death. All neonatal cases died of reasons other than pulmonary abnormalities 
with known postconceptional age and in the absence of documented growth retardation. 
No gross anatomical abnormalities were documented in any of these cases on 
standardized pediatric pathology evaluations. The lung samples were randomly selected 
from either side. There were five samples for each morphological distinct developmental 
stage: pseudoglandular stage (13.5 - 17 wk gestation; mean, 16 wk), canalicular stage 
(18 - 26 wk gestation; mean, 21.8 wk), saccular stage (29 - 36 wk gestation; mean, 30.4 
wk), and alveolar stage (37 - 41 wk of gestation; mean, 39 wk). Another five lung tissues 
from adult surgical resection specimens (normal lung tissue resected along with a tumor) 
were included (25 - 49 yr; mean, 38 yr). There were no pulmonary abnormalities in any of 
the lung specimens, especially no sign of pulmonary hypoplasia on histological 
screening. Tissue samples were snap-frozen and stored at -80 °C before RNA analysis. 
For immunohistochemical studies, tissues were fixed by immersion in 4% buffered 
formalin and embedded in paraffin. Subsequently, 5-µm-thick sections were mounted on 
3-amino-propyl-trioxysilane-coated glass slides (Sigma, St. Louis, MO) and processed 
for immunohistochemistry.  
 
RNA extraction and cDNA synthesis  
Total RNA was extracted from frozen lung tissues using TRIzol reagent (Invitrogen, 
Breda, The Netherlands), according to the manufacturer's instruction. Total RNA was 
quantified by measuring the absorbance at 260 nm, and the purity was checked with 
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260/280 nm absorbance ratio. cDNA synthesis was carried out in a reaction vol of 20 µl 
containing 500 ng total RNA, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM 
dithiothreitol, 100 ng random hexamer primer, 500 µM of each deoxynucleotide 
triphosphate (dATP, dGTP, dCTP, and dTTP), 10 U ribonuclease inhibitor, and 200 U 
Moloney murine leukemia virus reverse transcriptase (all reagents were obtained from 
Invitrogen). The samples were incubated for 60 min at 37 °C, followed by incubation for 
15 min at 99 °C. Negative control samples were prepared by omission of the Moloney 
murine leukemia virus reverse transcriptase.  
 
Real-time quantitative PCR  
Real-time PCR was performed using an iCycler IQ Real time PCR detection system (Bio-
Rad Laboratories, Inc., Veenendaal, The Netherlands) and qPCR Core kit for SYBR 
Green I (Eurogentec, Seraing, Belgium). Gene-specific primers used in this study (Table 
2.1) were designed using the sequences accessible in the NCBI Reference Sequence 
(www.ncbi.nlm.nih.gov/RefSeq) and Primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). A total reaction vol of 25 µl contained 1x reaction buffer, 
3.5 mM MgCl2, 200 µM of each deoxynucleotide triphosphate, 250 nM of each primer, 
and 1 µl cDNA. The PCR thermal cycle conditions were: 10 min of initial denaturation at 
95 °C, followed by 40 cycles of 30 sec at 95 °C, 30 sec at 58 °C for annealing, 30 sec at 
60 °C, and 15 sec at 75 °C. To verify the specificity of the amplified products, each PCR 
was followed by a melting curve analysis from 55 - 95 °C. Each sample was run as a 
triplicate, and mRNA of each target gene was determined simultaneously in a 96-well 
plate. Negative control samples and reactions mixed without cDNA templates were run in 
parallel.  
 
PCR results are shown as the relative expression level of normalized samples [∆ cycle 
threshold (Ct)] in relation to the expression of the "calibrator" sample of 13.5 wk gestation 
(2-∆∆Ct), which was arbitrarily set at 100% (arbitrary value = 1). The Ct value refers to the 
cycle number at which the PCR plot crosses the threshold line, ∆Ct is calculated by 
subtracting Ct value of the corresponding glyceraldehyde-3-phosphate dehydrogenase 
control (endogenous reference control) from the specific Ct value of the target, and ∆∆Ct 
is obtained by subtracting the ∆Ct of each experimental sample by the ∆Ct of the 
calibrator sample.30  
 
Statistical analysis 
Data from the real-time RT-PCR are shown as mean 2-∆∆Ct ± SEM or individually. The 
differences in mRNA expression between groups were analyzed with one-way ANOVA 
with post hoc least-significant difference test. The correlations between mRNA 
expression and gestational age were determined by nonparametric Spearman's 
correlation. P ≤ 0.05 was considered statistically significant (see Figure. 2.2, which 
includes correlation coefficients only for groups for which P ≤ 0.05). All statistics were 
calculated using a SPSS statistical package (version 11.0; SPSS, Inc., Chicago, IL). 
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Table 2.1 Primer sequences for real-time PCR 
Gene Primer sequences (5’Æ3’) Product size 
(bp) 
Reference 
sequences* 
GAPDH Fw: TGA ACG GGA AGC TCA CTG G  307 NM_002046 
 Rv: TCC ACC ACC CTG TTG CTG TA    
GRα Fw: GAA CTG GCA GCG GTT TTA TC  125 NM_000176 
 Rv: TCT CGG GGA ATT CAA TAC TCA    
TRα1 Fw: TCG AGC ACT ACG TCA ACC AC  127 NM_199334 
 Rv: TCG ACT TTC ATG TGG AGG AA    
TRβ Fw: ACC AGA GTG GTG GAT TTT GC  105 NM_000461 
 Rv: AAG GGA CAT GAT CTC CAT GC    
RARα Fw: TAC TGC CGA CTG CAG AAG TG  120 NM_000964 
 Rv: CGT CAG CGT GTA GCT CTC AG    
RARβ Fw: GGT TTC ACT GGC TTG ACC AT  129 NM_000965 
 Rv: AAG GCC GTC TGA GAA AGT CA    
RARγ Fw: TAC CAC TAT GGG GTC AGC   119 NM_000966 
 Rv: CTG GTC ACC TTG TTG ATG AT    
RXRα Fw: TTC GCT AAG CTC TTG CTC   113 NM_002957 
 Rv: ATA AGG AAG GTG TCA ATG GG    
RXRβ Fw: GAA GCT CAG GCA AAC ACT AC  111 NM_021976 
 Rv: TGC AGT CTT TGT TGT CCC     
RXRγ Fw: ACA AGC GTC AGC GCA ACC   121 NM_006917 
 Rv: GCC TCA CTC TCA GCT CGC TCT C   
 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase 
* Reference sequences number according to NCBI Reference sequence (RefSeq)  
 
Immunohistochemistry 
Immunohistochemistry was performed using a ChemMate Dako EnVision Detection Kit, 
Peroxidase/DAB, Rabbit/Mouse (K5007, Dako- Cytomation B.V., Heverlee, The 
Netherlands). In brief, after deparaffinization for 10 min in xylene and rinsing in 100% 
alcohol twice, slides were treated with 3% H2O2 in methanol for 20 min to block the 
endogenous peroxidase activity. For antigen retrieval, the slides were subjected to a 15-
min microwave treatment in Tris/EDTA buffer (pH 9.0) or citric acid buffer (pH 6.0). 
Sections were incubated for 30 min at room temperature with primary antibody (Table 
2.2) in a humidified chamber. After rinsing twice with PBS/0.1% Tween 20, slides were 
incubated for 30 min at room temperature with HRP-conjugated dextran polymer 
reagent. Sections were then rinsed twice with PBS before peroxidase was detected by 
incubation with 3,3'-diaminobenzidine tetrahydrochloride (1:50 dilution of ChemMate 
DAB+ Chromogen in ChemMate Substrate Buffer). Finally, slides were rinsed with 
running tap water and counterstained with hematoxylin, dehydrated through graded 
alcohol and xylene, and mounted. Negative controls were performed by omission of the 
primary antibodies.  
Hormone Receptors in Developing Human Lung  
 17
Table 2.2 Primary antibodies for immunohistochemistry 
Antibody Source Dilution Company 
GRα Rabbit 1:75 sc-1002; Santa Cruz Biotechnology, U.S.A. 
TR α1/α2 Mouse 1:20 Clone 1718; Labvision Neomarkers, CA, U.S.A. 
TRβ Mouse 1:50 Clone 2386; Labvision Neomarkers, CA, U.S.A. 
RARα Rabbit 1:100 sc-551; Santa Cruz Biotechnology, U.S.A. 
RARβ Rabbit 1:100 sc-552; Santa Cruz Biotechnology, U.S.A. 
RARγ Rabbit 1:200 sc-550; Santa Cruz Biotechnology, U.S.A. 
RXRα Rabbit 1:250 sc-553; Santa Cruz Biotechnology, U.S.A. 
RXRβ Mouse 1:250 Clone 147; Labvision Neomarkers, CA, U.S.A. 
RXRγ Rabbit 1:250 sc-555; Santa Cruz Biotechnology, U.S.A. 
 
 
RESULTS 
mRNA expressions 
The expressions of the mRNA for GRα, TRα1, TRβ, RARs, and RXRs were detected in 
all the samples examined. Figure 2.1 shows average mRNA expression (mean ± SEM) 
of the different morphological stages. The mRNA expression of all genes studied was 
low in the pseudoglandular group and increased during the canalicular and the saccular 
stages. For RARα and RARγ, mRNA expression increased with age until adult, whereas 
the expression of GRα, TRα1, RARβ, and all RXRs was highest in the saccular or the 
alveolar group. Although there was no significant difference in mRNA expression 
between developmental groups for all genes studied, there were discernable differences 
in mRNA expression during development. When individual data points from fetus and 
newborn samples (13.5 - 41 wk gestation) were plotted against gestational age (Figure 
2.2), there were significant positive correlations between age and mRNA expression of 
RARα (r = 0.665; P = 0.001), RXRα (r = 0.444; P = 0.050), and RXRγ (r = 0.464; P = 
0.039). Melting curve analysis showed the generation of specific products in all PCRs, as 
was confirmed by running several samples on agarose gel (data not shown).  
 
Immunohistochemistry 
Immunoreactivity of GRα, TRα, TRβ, RARs, and RXRs was detected in the nuclei of cells 
in all samples. GRα reactivity was detected mainly in epithelial cells (Figure 2.3A). TRα 
was expressed in both epithelial and mesenchymal cells (Figure 2.3B), whereas TRβ 
reactivity was detected in the epithelial cells and endothelial cells of arteries (Figure 
2.3C). Immunoreactivities of RARs and RXRs were detected in virtually all epithelial cells 
and in some mesenchymal cells (Figure 2.3, D–I). The expression pattern of each 
receptor was similar in all developmental groups. Because the immunohistochemistry 
was basically to demonstrate the regions and cellular distribution of the receptors, we did 
not attempt to quantify the staining intensity. 
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Figure 2.1 The ontogenic change of mRNA expression of GRα, TRα1, TRβ, RARs, and RXRs in 
human lungs. Samples were grouped according to their morphological stages and gestational age: 
pseudoglandular (13.5 - 17 wk), canalicular (18 - 26 wk), saccular (29 - 36 wk), alveolar (37 - 41 wk), 
and adult (25 - 49 yr); n = five per group. Data are shown as mean 2-∆∆Ct ± SEM (as outlined in 
Materials and Methods). There was no significant difference in mRNA expression in all encoded genes 
(P > 0.05). 
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Figure 2.2 Relation between GRα, TRα1, TRβ, RARs, and RXRs mRNA expression and gestational 
age of 20 samples from 13.5 - 41 wk of gestation. The r-values show Spearman’s correlation 
coefficient with gestational age.  
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Figure 2.3 (for color figures see page 106) Immunostaining of representative samples of human fetal 
lung. All picture were taken from sample of 18 weeks of gestation except for TRβ (32 wk) and RXRβ 
(13.5 wk). The immunoreactivity was visualized by diaminobenzidine, positive cells giving a brown 
color at the site of reaction. (A), GR immunoreactivity was expressed mainly in nuclei of epithelial 
cells. (B), TRα was detected in both epithelial and mesenchymal cells, while TRβ (C), was detected in 
airway epithelium and some vascular endothelial cells (arrow). Immunoreactivities of RARα (D), RARβ 
(E), RARγ (F), RXRα (G), RXRβ (H), and RXRγ (I) were detected virtually in all epithelial and in some 
of mesenchymal cells. (scale bar, 50 µm) 
 
 
DISCUSSION 
The developing lung undergoes a series of complex changes both during embryogenesis 
and after birth. Although a number of studies were conducted to evaluate the roles of 
glucocorticoids, thyroid hormone, and RA in lung formation, there is limited knowledge on 
the ontogeny of the expression of their receptors during human lung development. In this 
study, we investigated the mRNA expression of GRα, TRs, RARs, and RXRs in human 
lung throughout gestation, using real-time quantitative PCR and immunohistochemistry. 
We detected mRNA and protein expression of all receptors in human lung from the 
earliest stage, 13.5 wk gestation, onward.  
 
The GR is a ubiquitously expressed hormone-dependent transcription factor involved in 
the regulation of many physiological processes. In humans, Ballard and Ballard26 first 
reported GR mRNA expression in lungs of fetuses and neonates (age ranging from 12 - 
Hormone Receptors in Developing Human Lung  
 21
43 wk gestation) using cytoplasmic binding and nuclear uptake assays. In 1990, Labbe 
et al.27 measured GR concentration in fetuses (15 - 28 wk gestation), infants, and 
children (2 months to 9 yr). The receptor concentration in the fetuses was high, 
irrespective of gestational age, and the mean concentration was significantly lower 
postnatally. Moreover, to evaluate the functional role of GR, several experiments with 
mutant mice have revealed that lung maturation was delayed in mice with low or no GR 
expression.3,31 The lungs of the GR null mice are condensed and hypercellular, with 
reduced septal thinning, leading to an increase in the airway-to-capillary diffusion 
distance.  
 
Our quantitative PCR data showed a slightly different pattern, i.e. low GRα mRNA 
expression at the pseudoglandular stage, increasing during gestation, and lower in 
adults. We did not include infant specimens in our study. We found the 
immunohistochemical localization of the GR in the nuclei of airway epithelium and 
mesenchymal cells, albeit more prominent in the epithelium. This finding is consistent 
with previous studies performed in adult lungs, which showed GR to be localized in 
alveolar wall, airway epithelium, and vascular endothelial cells.32,33 Oakley et al.19 
showed that the GRβ resides in the nucleus of cells, irrespective of hormonal binding, 
whereas GRα is in the cytoplasm and translocates to the nucleus upon ligand binding. 
 
Thyroid hormone is essential for normal growth and development. Serum T3 and T4 are 
present in the fetal circulation before the onset of fetal thyroid hormone production, albeit 
at low levels.34,35 During the first trimester, maternal thyroid hormone is transferred into 
fetal circulation via the secondary yolk sac; and during the second trimester, it is 
transferred directly into fetal blood. Subsequently, there is an increasing contribution of 
thyroid hormone production by the fetal thyroid gland.35 The role of thyroid hormone in 
lung development is exerted predominantly in the late phase of lung development, with 
regard to the regulation of surfactant production. In rats, administration of T3 accelerates 
the process of septation, resulting in a greater alveolar surface area.36 TRα1 and TRβ act 
as T3-dependent transcription factors. TRs can bind to the DNA as homodimers or as 
heterodimers with other nuclear receptors, such as RXRs.18 Increases in TR binding 
capacity and occupancy by T3 during lung development in rabbits suggest a 
physiological role of thyroid hormone in lung development.6 Little is known about the 
cellular pattern of TR in the developing human lung. In this study, we demonstrated that 
TRα1 mRNA expression increases from pseudoglandular to alveolar stage and then 
declines in adult specimens. Both TRα and TRβ proteins were expressed in nuclei of 
epithelial cells. TRβ was also present in endothelial cells of the arteries. The expression 
of TRα in mesenchymal cells combined with the expression of TRβ in endothelial cells is 
of interest in light of the observation that changes in the T3 and T4 levels have an effect 
on the heart and vascular system.37 Endothelium-dependent dilation of conductance 
vessels is impaired in hypothyroidism but augmented in hyperthyroidism. However, 
dilation of resistance vessels in skeletal muscle appears unchanged in both hypo- and 
hyperthyroidism.38 Treatment of rats with T3 increased the endothelium-dependent 
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relaxation of the renal artery, probably by increasing the vascular cAMP content.39 
Particularly, the exposure to T3 for 8 wk led to an enhanced expression of endothelial 
nitric oxide synthase and thus the release of NO, which appeared to be the predominant 
endothelium-derived vasodilator. In another study, Heron et al.40 showed that 12 d of 
exposure to T3 in neonates resulted in a considerable proliferation of coronary capillaries, 
which declined after 28 d of treatment. The expression of the two receptors in the 
endothelium and surrounding tissue during gestation may contribute to the expansion of 
the pulmonary vasculature, which is already present early in development.41 
 
RA is an oxidative metabolite of vitamin A and is involved in the control of many 
biological processes. The regulation of the differentiation processes by RA involves the 
ability of these signaling molecules to alter the expression of a wide variety of genes. For 
example, RA regulates the expression of hox genes during embryonic branching 
morphogenesis to favor growth of proximal airways and to suppress distal epithelial bud 
formation.42,43  
 
RARs serve distinct functions in lung development. RXRs can act as homodimers or 
heterodimers with a variety of nuclear receptors, including RARs and TRs.43,44 RARα 
mediates alveolar growth during the perinatal period of alveolarization.45 RARβ inhibits 
septation,46 whereas RARγ is needed for normal lung elastin production and 
alveolarization.47 Administration of all-trans RA to normal neonatal rats enhances 
alveolar septal formation without increasing alveolar surface area.11 RARα/RXRα and 
RARα/β double-knockout mice were shown to have lung hypoplasia or agenesis, 
demonstrating the importance of these receptors during the early phases of lung 
development.13,14,48 
 
Previously, a study from Kimura et al.28 has shown that the mRNA levels of RXRγ at 
proximal (trachea and main bronchus) and distal sites, of RARβ at distal sites, and of 
RARγ at proximal sites were significantly higher in human fetal lung (13 - 16 wk 
gestation) compared with adults. In this study, we found no significant difference in 
mRNA expression between different developmental stages for the RARs and RXRs 
studied. However, we found positive correlations between gestation age and expression 
of RARα, RXRα, and RXRγ from 13.5 - 41 wk. 
 
In conclusion, mRNA expression of GRα, TRs, RARs, and RXRs were detected in 
human lung from 13.5 wk gestation onward. These results indicate that, as far as 
receptors are concerned, human fetal lung has the potential to respond to 
glucocorticoids, thyroid hormone, and RA as early as 13.5 wk gestation and potentially 
earlier, which implies an early potential for therapeutic benefits by exogenous analogs. 
However, more investigation is needed because there is a possibility of toxic effects by 
excess of endogenous ligands as well. We consider the results from this study as 
baseline data for further comparative studies involving abnormal lung development, such 
as in cases of pulmonary hypoplasia with or without diaphragmatic hernia. 
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ABSTRACT 
The degree of associated pulmonary hypoplasia and persistent pulmonary hypertension 
are major determination factors for survival in congenital diaphragmatic hernia (CDH) 
patients. Glucocorticoids, thyroid hormone, and vitamin A have been shown to be 
involved in human lung development. To determine their therapeutic potential in 
hypoplastic lungs of CDH patients, the temporal and spatial expression of glucocorticoid 
receptor, thyroid hormone receptors, retinoic acid receptors, and retinoid X receptors 
were evaluated in lungs of CDH patients, hypoplastic lungs from other causes, and 
normal lungs. As a series of supportive experiments, the expressions of these receptors 
were analyzed in lungs of nitrofen-induced CDH rats. Immunohistochemistry (human and 
rat) and in situ hybridization (rat) demonstrated no overt difference between CDH, 
hypoplastic, and control lungs, either in the localization nor the timing of the first 
expression of all analyzed receptors. The mRNA expression of each receptor was 
detected in all human CDH lungs by quantitative PCR. Our results suggest that, as far as 
receptors are concerned, hypoplastic lungs of fetuses and newborns with CDH are 
potentially as responsive to glucocorticoids, thyroid hormone, and retinoic acid as the 
lungs of normal children.  
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INTRODUCTION 
CDH occurs approximately 1 in 2500 live births. This malformation, first described in 
1848 by Vincent Bochdalek, is characterized by a diaphragmatic defect, herniation of 
abdominal viscera into the thoracic cavity, a variable extent of PH, and PPH. Despite the 
recent progress in new therapeutic strategies such as inhaled nitric oxide, exogenous 
surfactant therapy, or extracorporeal membrane oxygenation in selected infants, 
newborns with CDH continue to experience a high mortality.1,2 The major factors limiting 
survival of CDH patients are respiratory insufficiency secondary to PH and PPH. The 
lungs of newborns with CDH are characterized by a variable amount of immature alveoli 
with thickened walls and increased interstitial tissue, whereas surfactant deficiency may 
occur mainly due to surfactant inactivation instead of a primary surfactant deficiency.3 
 
With the increased use of prenatal ultrasound, more CDH cases are being diagnosed 
prenatally. Failure of postnatal therapies to significantly improve the prognosis of these 
infants has led to new strategies to rescue or stimulate fetal lung growth before delivery. 
For over two decades, pioneer efforts have been made to repair the diaphragmatic 
defect prenatally in fetuses with CDH but the outcome has been hampered by technical 
difficulties and a high rate of preterm delivery.4 The observation that infants with 
laryngeal atresia develop hyperplastic lungs led to the concept of "PLUG" (plug the lung 
until it grows) and fetal endoscopic temporary tracheal occlusion (FETENDO).5,6 A 
randomized clinical trial sponsored by the National Institutes of Health demonstrated no 
survival benefit compared with elective delivery in the specialist centers with optimal 
postnatal care.4 However, the trial continues in Europe with fetoscopic tracheal occlusion 
(FETO), hoping that further technical refinement may improve survival in high-risk 
patients.7,8  
 
Inasmuch as the benefit of fetal surgical interventions remains unclear, pharmacological 
approaches to stimulate prenatal lung growth and maturation have been considered as 
another strategy to improve lung development in case of CDH. GC are used worldwide to 
accelerate pulmonary development in threatened premature labor to decrease the 
incidence of respiratory distress syndrome.9,10 Within this context, the potential beneficial 
effects of prenatal GC treatment on lung maturation have been studied in the nitrofen (2, 
4-dichlorophenyl- p-nitrophenyl ether)-induced CDH rat model and the surgical sheep 
model for CDH. The nitrofen model, based on the teratogenic effects of the herbicide, 
lead to a condition in rodents very similar to that observed in human CDH, including the 
features of PH and PPH.11 A disturbance in maternal thyroid function as well as in fetal 
thyroid function has been suggested to be involved in the teratogenic effect of nitrofen. 
Firstly, there is a stereo-chemical similarity between nitrofen and thyroid hormone. 
Secondly, nitrofen-treated dams have less malformed fetuses if T4 is given during 
pregnancy; and, thirdly, nitrofen-treated pregnant rats have lowered T4 and TSH levels.12 
In addition, our group has demonstrated that nitrofen decreases the binding of T3 to the 
thyroid hormone receptor α1 and β1 in a noncompetitive way.13 
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Recently, more attention has been drawn to vitamin A and its active metabolite, RA. The 
classical data published by Anderson14 showed that 25% of rats born from dams with a 
vitamin A-deficient diet have a defect in the diaphragm. The incidence of a diaphragmatic 
defect reduced from 31% to 24% when a single dose of vitamin A administrated to 
vitamin A-deficient female rats on d 15 of pregnancy.15 Thebaud et al.16,17 have shown 
that antenatal treatment with vitamin A in the nitrofen-induced CDH model reduces the 
incidence of CDH at term as well as improving lung growth and maturation. In humans, 
lower plasma vitamin A levels were found in prematurely born infants, especially in 
patients with respiratory distress and in a selective number of term newborns with 
pulmonary hypoplasia associated with congenital diaphragmatic hernia.18,19 Although 
exciting, the confirmation of these findings awaits international collaboration, which is 
ongoing at present.  
 
The actions of glucocorticoids, thyroid hormone, and retinoic acid are mediated through 
their specific nuclear receptors and the level of nuclear receptor expression determines 
cellular sensitivity to certain hormones.20 Since the optimal way of prenatal modulation of 
CDH is still a matter of ongoing debate, detailed information on the tissue distribution of 
these receptors in case of abnormal pulmonary development is warranted. Therefore, we 
examined the expression of GRα, TR, RAR, and RXR in human lungs with CDH, 
pulmonary hypoplasia due to other causes and compared these data with an ontogenic 
study of the same receptors during normal human lung development published by our 
group.21 As a series of supportive experiments, we examined the expression of these 
receptors in the lungs of nitrofen-induced CDH rats.  
 
 
MATERIALS AND METHODS 
Human 
Following approval of the experimental design and protocols by the University Ethical 
Committee, lung tissues were retrieved from the archives of the Department of 
Pathology, Erasmus MC, Rotterdam. There were 18 CDH lung samples collected from 
either termination of pregnancy or patients who died within 48 h after birth (gestational 
age, 18 - 41 wk; mean, 34.2 wk). Demographic information of CDH cases is shown in 
Table 3.1. Immunohistochemical studies were performed in all CDH samples, whereas 
PCR was performed in five samples (cases 1 - 5) of which frozen tissue was available. 
Twenty paraffin-embedded lung samples from fetuses or newborns with pulmonary 
hypoplasia due to other causes, including Pena-Shokeir syndrome, hydrothorax, renal 
dysgenesis, and oligohydramnios (gestational age, 18 - 40 wk; mean, 30.5 wk) were 
included for immunohistochemical studies. None of the patients included in this study 
was subjected to prenatal steroid or extracorporeal membrane oxygenation therapy. 
Lung tissue from 15 age-matched fetuses and newborns (from termination of pregnancy 
or autopsies) without pulmonary abnormalities served as control (gestational age, 18 - 41 
wk; mean, 30.4 wk). All samples were harvested within 24 h after death. 
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Table 3.1 Clinical information of congenital diaphragmatic hernia patients 
case Gestational age  
(wk) 
Birth weight  
(g) 
Lung/body 
weight ratio* 
Time of death after birth 
1† 23 558 0.012 Termination of pregnancy 
2† 23.5 350 0.013 Termination of pregnancy 
3† 34.5 2800 0.008 < 24 h 
4† 38 2450 0.011 Minutes 
5† 41 3510 0.006 48 h 
6 18 161 0.012 Termination of pregnancy 
7 21 416 0.007 Termination of pregnancy 
8 28 830 0.003 2 h 
9 34 1250 0.005 Minutes 
10 36 2515 0.003 1 h 
11 38 2870 0.005 30 min 
12 38 2900 NA 24 h 
13 39 2890 0.003 15 min 
14 40 3225 < 0.01 6 h 
15 40 1220 NA 24 h 
16 40 2050 0.005 Minutes 
17 41 2765 0.005 1.5 h 
18 42 3355 0.002 30 min 
 
* Normal lung/body weight ratio: before 25 wk of gestation = 0.015; from 25 wk of gestation = 0.012 
† Frozen lung tissue available for quantitative PCR 
 
Nitrofen-induced rats 
Adult Wistar rats were obtained from the HSD animal farm in Zeist, the Netherlands. 
Animal experiments were performed in accordance with the guidelines of the animal 
research committee. The positive sperm plug day was designated as d 1 of gestation. To 
induce CDH and pulmonary hypoplasia, 100 mg of nitrofen dissolved in 1 ml olive oil was 
given to the dams by gavages on d 10.11 Fetuses were delivered by cesarean section at 
15, 18, and 20 d of gestation, which corresponds to the pseudoglandular, the canalicular, 
and the saccular stage of rat pulmonary development respectively (term = 23 d). All 
tissues were fixed in 4% buffered formaldehyde and embedded in Paraplast Plus 
(Monoject, Kildare, Ireland). Seven-micrometer sections were cut and mounted onto 
RNase free 3-aminopropyltriethoxysilane coated slides (Sigma Chemical Co., St. Louis, 
MO). There were three to five random fetuses in each experimental group. From the 
group treated with nitrofen, only fetuses with a diaphragmatic hernia were included in this 
study.  
 
Immunohistochemistry 
Immunohistochemistry was performed on human and rat tissues for GRα, TRα, TRβ, 
RAR (α,β,γ), and RXR (α,β,γ) using a ChemMate DAKO EnVision Detection Kit, 
Peroxidase/DAB, Rabbit/Mouse (DakoCytomation B.V., Heverlee, Belgium). Primary 
antibodies and immunohistochemical processes were described in detail in our previous 
study.21 Negative controls were performed by omission of the primary antibodies. No 
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quantification of the staining intensity was attempted because the immunohistochemical 
study was basically to demonstrate the cellular distribution of the receptors.  
 
In situ hybridization 
Rat tissues were analyzed for GR, TRα, TRβ, RXRα, and RXRβ. GR cDNA (2.4 kb) was 
isolated from rat liver and recloned in pBluescript SK+ in the BamHI restriction site of the 
multiple cloning site (kind gift from Dr. Paul Godowski).22 Probes for the TRα and TRβ 
mRNA in EcoRI-HindIII cDNA fragments were obtained from H.C. Towle.23 RXRα and 
RXRβ mRNA were detected using an EcoRI-EcoRI cDNA fragment (1850 bp) and 
EcoRI-HindIII cDNA fragment (1360 bp), respectively. The hybridization conditions were 
as described elsewhere.24 The sections of rat fetuses were digested with 0.1% (wt/vol) 
pepsin (Sigma Chemical Co.) in 0.01 M HCl for 7 min (d 15 of gestation), 10 min (d 18 of 
gestation), and 15 min (d 20 of gestation) at 37 °C. The hybridization with [α-35S] dUTP 
labeled anti-sense probes was 16 - 18 h at 54 °C. The probe concentration was 
approximately 50 pg/µl and the specific activity of the anti-sense RNA probe was 
approximately 500 dpm/pg. After hybridization, the sections were washed and treated 
with RNase A. After exposure to photographic emulsion (Ilford Nuclear Research 
Emulsion G-5, Ilford, Cheshire, UK), the sections were counterstained with nuclear fast 
red, dehydrated in a graded series of ethanol and xylol, and mounted in Malinol 
(Chroma-Gesellschaft, Schmidt Gmbh+Co, Köngen, Germany).  
 
Real-time quantitative PCR 
Five CDH lungs and 15 control human lungs were analyzed for mRNA expression of 
GRα, TRα1, TRβ, RAR (α,β,γ), and RXR (α,β,γ). Total RNA was extracted from frozen 
human lung tissues using TRIzol reagent (Invitrogen, Breda, the Netherlands), according 
to the manufacturer's instruction. Total RNA was quantified by measuring the 
absorbance at 260 nm and the purity was checked with 260/280 nm absorbance ratio. 
Reverse transcription and PCR conditions were carried out exactly as described 
before.21 PCR was run in triplicate for each sample. Negative control samples and 
reactions mixed without cDNA templates were run in parallel.  
 
PCR results are shown as the relative expression level (2-∆∆Ct) of normalized samples 
(∆Ct) in relation to the expression of the "calibrator" sample. The Ct value refers to the 
cycle number at which the PCR plot crosses the threshold line. ∆Ct is calculated by 
subtracting Ct value of the corresponding GAPDH control (endogenous reference 
control) from the specific Ct value of the target, and ∆∆Ct is obtained by subtracting the 
∆Ct of each experimental sample from the ∆Ct of the "calibrator" sample. In this study, 
the control lung of 18 wk of gestation were used as a calibrator, which was arbitrarily set 
at 100% (arbitrary value = 1).  
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Figure 3.1 Relative mRNA expression of GRα, TRα1, TRβ, RARs (α,β,γ), and RXRs (α,β,γ) in 
human CDH and control lungs. All analyzed receptors were expressed in five lungs from CDH cases 
(●) and 15 control lungs (○). The expression levels are shown as relative value in an arbitrary unit 
compare to control lung of 18 wk of gestation (as outlined in "Materials and Methods").  
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RESULTS 
Human 
Five CDH lungs and 15 age-matched controls were analyzed with quantitative PCR. The 
mRNA expression for GRα, TRα1, TRβ, RAR (α,β,γ), and RXR (α,β,γ) was detected in 
all samples and the relative mRNA expression level of each gene is illustrated in Figure 
3.1. No statistic analysis was done due to limited number of CDH samples. The lungs of 
18 CDH cases and 20 patients with pulmonary hypoplasia secondary to causes other 
than CDH were included for immunohistochemical studies. The expression of GRα, TRα, 
TRβ, RAR (α,β,γ), and RXR (α,β,γ) was detected in a similar fashion in all control, CDH, 
and pulmonary hypoplasia samples. GRα reactivity was detected mainly in epithelial cells 
(results not shown). TRα was expressed in both mesenchymal and epithelial cells 
(Figure 3.2, A-C), whereas TRβ reactivity was detected in the epithelial cells as well as in 
the endothelial cells of arteries (results not shown). RAR (α,β,γ) and RXR (α,β,γ) were 
expressed in virtually all epithelial and mesenchymal cells (Figure 3.2, F-H, for RXRγ, for 
others results not shown). The spatio-temporal expression patterns of all receptors were 
similar in the CDH lungs, pulmonary hypoplasia due to other causes, and normal lungs. 
 
Nitrofen-induced rat 
In a series of supportive experiments, the immunohistochemical studies demonstrated 
the expression of GRα, TRα, TRβ, RAR (α,β,γ), and RXR (α,β,γ) at the protein level in 
both control and nitrofen-induced CDH rat lungs. The staining pattern of each receptor 
was comparable to that observed in human lungs as shown in Figure 3.2 for TRα (Figure 
3.2, D and E) and RXRγ (Figure 3.2, I and J), for others the results are data not shown. 
The results of the RNA in situ hybridization studies at d 15 and d 18 of gestation are 
shown in Figures 3.3 and 3.4, respectively. GR mRNA was observed in the endodermal 
part of the developing lung (d 15 of gestation) (Figure 3.3, A and B). On d 18 of 
gestation, GR expression was ubiquitous in both epithelium and mesenchyme, albeit 
more pronounced in the epithelium (Figure 3.4, A and B). The mRNA expression of 
RXRα and RXRβ was detected in both mesenchyme and epithelium from d 15 of 
gestation onward (Figure 3.3, C-F, and Figure 3.4, C-F), which corroborates the 
immunohistochemical findings. In contrast to the broad expression of TRα in both 
epithelial and mesenchymal cells as shown by the immunohistochemical studies (Figure 
3.2, A-E), the expression of TRα mRNA in in situ hybridization studies was confined to 
the pulmonary mesenchyme (Figure 3.3, G and H, and Figure 3.4, G and H). The 
expression of TRβ mRNA was detected predominantly in the pulmonary epithelium of the 
distal conducting airways (Figure 3.3, I and J and Figure 3.4, I and J). Expression of TRβ 
mRNA was observed at all time points in pulmonary arteries, while expression of TRα 
mRNA was continuously observed in pulmonary veins. An accurate description of the 
expression patterns became more difficult near term (d 20 of gestation) because the 
walls of the airways become very thin due to expansion of the gas-exchange surface 
(results not shown). In nitrofen-induced rat lungs, the spatial and temporal expression 
pattern was similar to that observed in control lungs for all investigated receptors 
(Figures 3.3 and 3.4). 
Hormone Receptors in CDH Lungs  
 35
 
 
Figure 3.2 (for color figures see page 107) TRα and RXRγ expression pattern in human and rat 
lungs. TRα (A-E) and RXRγ (F-J) are seen in both epithelial and mesenchymal cells. There is no 
difference in the localization of TRα or RXRγ in the lungs of human control; 23 wk (A, F), CDH: 34 wk 
(B, G), or pulmonary hypoplasia due to other causes: 27 wk (C, H). Comparable patterns are observed 
in control (D, I) and nitrofen-induced CDH (E, J) rat lungs (d 18 of gestation). All pictures were taken at 
the same magnification; scale bar = 100 µm. 
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Figure 3.3 In situ hybridization studies of hormone receptors expression in normal (A, C, E, G) and 
nitrofen-induced CDH rat lungs (B, D, F, H) at d 15 of gestation. GR mRNA is observed in the 
endoderm lining the branching airways (A, B). RXRα mRNA (C, D) and RXRβ mRNA (E, F) are 
observed in both germ layers. TRα mRNA (G, H) is exclusively expressed in the mesenchyme in 
contrast to TRβ mRNA (I, J), which is expressed in the epithelium. All pictures were taken at the same 
magnification; scale bar = 500 µm. 
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Figure 3.4 In situ hybridization studies of hormone receptor expression in normal (A, C, E, G) and 
nitrofen-induced CDH rat lungs (B, D, F, H) at d 18 of gestation. At this stage, GR mRNA is faintly 
expressed in the entire lung (A, B). RXRα mRNA (C, D) and RXRβ mRNA (E, F) are expressed in both 
mesenchyme and epithelium. TRα mRNA (G, H) is expressed in the mesenchyme, while TR beta 
mRNA (I, J) is exclusively expressed in the epithelium. All pictures were taken at the same 
magnification; scale bar = 500 µm. 
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DISCUSSION 
In this present study, no obvious differences in the spatial and temporal expression 
pattern of GRα, TR, RAR (α,β,γ), and RXR (α,β,γ) were observed between human CDH 
lungs, pulmonary hypoplasia from other causes and control lungs. These results are 
supported by a series of experiments undertaken in the nitrofen rat model for CDH. This 
study was inspired by the promising results obtained by the administration of 
glucocorticoids, thyroid hormone or vitamin A to nitrofen-treated rats.13,16,17,25-27 In our 
previous study, we have shown the expression of the nuclear hormone receptors in 
human lung from 13.5 wk until term with no change in localization throughout 
development.21 However, there is still limited information about the presence of these 
receptors in both human and rat CDH lungs.  
 
Antenatal corticosteroids are recommended by National Institutes of Health consensus to 
all fetuses between 24 and 34 wk of gestation at risk of preterm delivery.10,18 This will 
lead to an induction of surfactant production, an acceleration of lung maturation and an 
increase in lung compliance. In the present study, we demonstrate that the GRα is 
indeed expressed in a similar fashion in both normal lung tissues as well as in 
hypoplastic lungs of CDH cases or pulmonary hypoplasia due to other causes. The same 
holds true for control rat lungs and nitrofen-induced CDH lungs. At mRNA level, using 
quantitative PCR, we found no significant difference in GRα expression between CDH 
and control lungs. These findings are suggestive for a potential similar responsiveness to 
GC in lungs of CDH fetuses. There was one report of three CDH patients that suggested 
the benefit of prenatal GC for fetuses with CDH.28 But recently, the randomized trial and 
cohort study by the CDH study group demonstrated no significant benefit of late prenatal 
GC (after 34 wk of gestation) to fetuses with CDH, although more cases have to be 
included.29 With the paucity of human data, the side effects of GC and the lack of 
information on dosage and timing, antenatal GC are not recommended beyond 34 wk of 
pregnancy.30,31 
 
The role of thyroid hormone in lung development is exerted predominantly during the 
later phases of lung development, in which the regulation of surfactant production takes 
place. In rats, administration of T3 accelerates the process of septation, resulting in a 
greater alveolar surface area.32 Our study demonstrates that the localization of TR is not 
changed in hypoplastic lungs of fetuses with nitrofen-induced CDH. These results are 
compatible with the results from previous study by Tovar et al.,33 which demonstrated 
that nitrofen leads to decreased levels of T3 and T4 in the plasma but not at the tissue 
level. This is an indication that induction of pulmonary hypoplasia in nitrofen-induced 
CDH is not the result of an alteration in the localization of TR. In contrast to this, we 
observed lower mRNA expression of TRα1 in human CDH lungs than in control lungs, 
which was in agreement with a previous study in nitrofen-induced CDH rats.34 Although 
the latter data are suggestive for a diminished TRα1 expression, we are aware that far-
reaching conclusions cannot be drawn due to the limitations of our study, in particular the 
limited number of CDH lung samples available for PCR analysis.  
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Vitamin A is important for lung development. All-trans-RA acts via RAR, whereas 9-cis-
RA exerts its effects via both RAR and RXR. RXR can act as homodimers or 
heterodimers with a variety of nuclear receptors, including RAR and TR.35,36 In animal 
studies, the lack or the excess of vitamin A during embryonic development results in 
congenital malformations such as infertility, anophthalmia, and lung hypoplasia.18,37,38 
Transgenic RARα/RXRα and RARα/β double knockout mice were shown to have lung 
hypoplasia or agenesis.37-39 Our collaborative studies in the nitrofen rat model for CDH 
demonstrated that prenatal administration of vitamin A reduces the incidence of CDH 
and increases the levels of surfactant protein A and C in the offspring.16,17 In human 
pneumocytes cultured experiments, vitamin A administered after nitrofen exposure 
significantly increased the expression of surfactant protein B.40 In our present study, we 
showed that the expression pattern for all RAR and RXR is not changed in hypoplastic 
lungs of nitrofen-induced CDH rats. Similar findings are shown in human tissues for all 
RAR and RXR by immunohistochemical studies. Owing to the limited number of CDH 
samples, no statistical analysis was done. Although we observed a low RXRγ mRNA 
expression in human CDH lungs, there is possibly a redundancy for most functions of 
RXRγ by the other receptors of the family. The studies in RAR/RXR mutant mice 
revealed that there is a high degree of functional redundancy among these receptors.36 
 
Our findings suggest that there is a potential for biologic effects of exogenous 
glucocorticoids, thyroid hormone, and retinoic acid in CDH lungs. Experimental studies 
have illustrated the potential benefits of antenatal corticosteroids and vitamin A to 
overcome pulmonary hypoplasia in animal models of CDH. Our results indicate that there 
might be a potential for similar effects in cases of human CDH patients as well. For 
instance, the current evaluation of vitamin A levels in newborn babies with CDH 
compared with age-matched controls19 and the experimental data obtained by Greer et 
al.41 potentially guide the use of prenatal modulation of pulmonary growth in human CDH 
in the near future. Very recently, a prospective international observational study on 
vitamin A levels in cord blood obtained institutional review board approval in Canada 
(Greer JJ, personal communication). Further advancement in therapies for CDH patients 
may arise from improved understanding of the mechanism of abnormal lung 
development.42 
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ABSTRACT 
Pulmonary vascular development is essential for proper lung development and its 
disturbance can lead to neonatal morbidity and mortality, as exemplified in congenital 
diaphragmatic hernia. Hypoxia-inducible factors (HIFs) appear to be key molecules in 
physiologic and some forms of pathologic angiogenesis. Little is known about the 
qualitative and quantitative expression of HIFs in normal human fetal lung development. 
Therefore, we investigated the expressions of HIF-1α, HIF-2α and HIF-3α along with 
their upstream regulators and downstream targets, von Hippel-Lindau protein (pVHL), 
vascular endothelial growth factor A (VEGF-A) and its receptor, VEGFR-2, in 20 normal 
human fetal lungs (13.5 wk gestation till term) and five adult lungs. Quantitative PCR 
demonstrated a positive correlation between HIF-2α and VEGF-A expressions and 
gestational age. Although there appeared to be a decreasing trend in HIF-3α expression 
during pregnancy, it did not reach statistical significance. Immunohistochemistry for HIF-
1α and HIF-2α revealed that while HIF-1α is expressed in the epithelium only, HIF-2α  is 
expressed in both interstitium and epithelium. Our data suggest that hypoxia-inducible 
factors, most notably HIF-2α, appear to exert an important role in angiogenesis during 
human fetal lung development especially in the last phases of pregnancy, preparing the 
fetus for extra-uterine life. This action may occur through paracrine regulation between 
interstitial and epithelial cells, through an effect on downstream target genes, such as 
VEGF-A. As such our results form the baseline data for the evaluation and interpretation 
of abnormal pulmonary vascular development. 
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INTRODUCTION 
Fetal lung development is an intricate process orchestrated by numerous growth and 
transcription factors, as well as morphogens.1 Structurally, the airway branches and 
pulmonary vessels are closely aligned, suggesting an intimate interaction during lung 
development. A vascular network has been shown to be present from the earliest stage 
of lung development and pulmonary vascular development seems to be rate-limiting for 
airway branching.2-6 The process of vascular development, in particular angiogenesis, is 
mainly driven by hypoxia. Moreover, the low-oxygen environment during fetal life is 
essential for normal development of the lung.4,7 
 
Vascular endothelial growth factor A (VEGF-A) is a potent hypoxia-inducible growth 
factor for vascular patterning during lung development.8 For instance, VEGF blockage 
impaired alveolar development and decreased pulmonary angiogenesis in newborn rats, 
mimicking bronchopulmonary dysplasia.9 Conversely, postnatal VEGF gene therapy 
improved survival and increased lung capillaries and alveolarization in this rat model. 
VEGF-A binds and activates two tyrosine kinase receptors, namely VEGFR-1, also 
known as fms-like-tyrosine kinase (Flt)-1, and VEGFR-2, also known as KDR in humans, 
or fetal liver kinase (Flk)-1 in mice.10,11 VEGFR-2 null mutant mice die in utero due to lack 
of vasculogenesis and defective in development of endothelial cells, indicative of the key 
role of VEGFR-2 in differentiation and/or proliferation of endothelial cells and vascular 
biology.12  
 
One of the most potent activators of VEGF transcription is hypoxia-inducible factor (HIF), 
which is a heterodimer composed of one of three oxygen-sensitive alpha subunits (HIF-
1α, HIF-2α, HIF-3α) and a constitutive nuclear protein, the beta subunit (HIF-1β/ARNT). 
The alpha subunit is rapidly hydroxylated by prolyl hydroxylases (PHDs) under normoxic 
conditions, leading to its association with the von Hippel-Lindau protein (pVHL). 
Subsequently, the hydroxylated alpha subunit is targeted for proteasomal degradation. 
Since the PHDs require oxygen for their activity, the crucial hydroxylation step does not 
occur under hypoxic conditions and the alpha subunit remains stable and dimerizes with 
the beta subunit to form an active HIF transcription factor.13,14 Modifications to the HIF 
pathway have underlined its importance in development. Embryos with inactivating 
mutations of HIF-1α or HIF-2α all die in mid or late gestation.15-18 
 
Despite these studies in mice, very little is known about the VHL-HIF-VEGF pathway 
expression in human lung development. Although differential expression of the proteins 
HIF-1α and VHL has been observed in the lungs of CDH patients,19 quantitative analysis 
of HIFs during normal and abnormal lung development is limited. We therefore 
investigated the mRNA expressions of VHL, HIF-1α, HIF-2α, HIF-3α, VEGF-A and its 
receptor, VEGFR-2, by quantitative RT-PCR. In addition, we studied the expressions of 
HIF-1α and HIF-2α by immunohistochemistry in normal human fetal lungs, to determine 
their spatial expression in normal lung development. 
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MATERIAL AND METHODS 
Tissue specimens 
Normal human lung tissue (n = 25) was retrieved from the tissue bank of the Department 
of Pathology, Erasmus MC, Rotterdam, following approval of the experimental design 
and protocols by the Erasmus MC Medical Ethical Review BoardCommittee. Fetal and 
neonatal lungs (n = 20) were obtained from terminations of pregnancy and newborns 
who had died within 1 hour of birth. None of these fetuses or newborns had 
abnormalities related to the lungs and none of the newborns had received supplemental 
oxygen or mechanical ventilation. All tissues had been harvested within 24 hours after 
death. The lung samples were divided into four groups (n = 5) according to the lung 
developmental stages – i.e. pseudoglandular (7 - 17 wk gestation), canalicular (18 - 26 
wk gestation), saccular (27 - 35 wk gestation), and alveolar (36 wk gestation –term). As a 
fifth group, unaffected lung adjacent to surgical resections for lung carcinoma was 
obtained from 5 adults (28 - 49 yr). Tissue specimens were snap-frozen, stored in liquid 
nitrogen until used for RNA isolation. For immunohistochemical studies, tissues were 
fixed by immersion in 4% buffered formalin and embedded in paraffin. Five-µm-thick 
paraffin sections were mounted on 3-amino-propyl-trioxysilane coated slides (Sigma, St. 
Louis, MO) and processed for immunohistochemistry. 
 
RNA isolation and quantitative RT-PCR 
Total RNA was extracted from frozen lung tissues using Trizol reagent (Life 
Technologies, Rockville, MD) following the manufacturer's instructions. RNA was 
quantified by measuring the absorbance at 260 nm and the purity was checked by the 
260/280 nm absorbance ratio. cDNA synthesis was carried out in a final volume of 20 µl, 
containing 1 µg of total RNA, 50mM Tris-HCL (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM 
DTT, 100 ng random hexamer primers, 0.5 mM dNTPs (Roche Diagnostics, Basel, 
Switzerland), 10 U RNase inhibitor, and 200 U Moloney Murine Leukaemia Virus reverse 
transcriptase (all reagents from Invitrogen, San Diego, CA). These samples were 
incubated for 1 hr at 37 °C followed by incubation for 15 min at 99 °C. Negative controls 
were prepared by omission of the Moloney Murine Leukaemia Virus enzyme. 
 
Real-time PCR was performed using an iCycler IQ Real time PCR detection system (Bio-
Rad, Veenendaal, The Netherlands) and qPCR Core kit for SYBR Green I (Eurogentech, 
Seraing, Belgium). Gene-specific primers used in this study are shown in Table 4.1. 
Gene amplification was carried out by activation of Hot Goldstar enzyme at 95 °C for 10 
min, followed by 40 cycles of 95 °C for 30 sec, 58 °C for 30 sec, 60 °C for 45 sec, and 
75 °C for 15 sec. Each sample was run in triplicate and negative control samples and 
samples without cDNA templates were run in parallel. After each assay, products were 
run on a 1.5% agarose gel to check the size and specificity.  
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Table 4.1 Primer sequences for quantitative PCR 
Gene Forward Primer (5’ Æ 3’) Reverse Primer (5’ Æ 3’) 
HIF-1α GCT CAT CAG TTG CCA CTT CC CCT CAT GGT CAC ATG GAT GAG 
HIF-2α CCA ATC CAG CAC CCA TCC CAC GTT GTA GAT GAC CGT CCC CTG 
HIF-3α ACC TGG AAG GTG CTG AAC TG AAT CCT GTC GTC ACA GTA GG 
VHL CTC TCA ATG TTG ACG GAC AG CCA GAT CTT CGT AGA GC 
VEGF-A AGA ATC ATC ACG AAG TGG TG TGT TGT GCT GTA GGA AGC TC 
VEGFR-2 CAG AGT GGC AGT GAG CAA AG TAC ACG ACT CCA TGT TGG TC 
POLR2A CGG ATG AAC TGA AGC GAA TG AGC AGA AGA AGC AGA CAC AG 
 
PCR results are shown as the relative expression level of normalized samples (∆Ct) in 
relation to the expression of the ’calibrator’ sample of 13.5 wk gestation (2-∆∆Ct), which 
was arbitrarily set at 100% (arbitrary value = 1). The Ct value refers to the cycle number 
at which the PCR plot crosses the threshold line; ∆Ct is calculated by subtracting the Ct 
value of the corresponding endogenous reference gene; RNA Polymerase II, Subunit A 
(POLR2A) from the specific Ct value of the target gene, and ∆∆Ct is obtained by 
subtracting the ∆Ct of each experimental sample from the ∆Ct of the ’calibrator’ sample. 
 
Statistical analysis 
Data from real-time RT-PCR are shown as mean 2-∆∆Ct ± SEM. Differences in mRNA 
expression between groups were analyzed with one-way ANOVA with the post hoc least-
significant difference (LSD) test. The correlations between mRNA expression and 
gestational age were determined by nonparametric Spearman's correlation. P ≤ 0.05 was 
considered statistically significant. All statistics were calculated using SPSS (version 
11.0; SPSS Inc., Chicago, IL). 
 
Immunohistochemistry 
Antibodies used were mouse monoclonal anti-human HIF-1α H1α67 (Neomarkers, 
Fremont, CA) 1:1000, and rabbit polyclonal anti-mouse HIF-2α PM8 antiserum20 
1:10,000. Formalin fixed paraffin embedded sections were dewaxed in two sequential 
xylene baths, and rehydrated using graded ethanol washes. For antigen retrieval, 
sections were immersed in preheated DAKO target retrieval solution (DAKO, Carpinteria, 
CA) and treated for 90 seconds in a pressure cooker. Incubation time with primary 
antibodies was 1 hour at room temperature. Antigen/antibody complexes were revealed 
by means of the Catalyzed Signal Amplification system (DAKO) according to the 
manufacturer's instructions. Sections were counterstained with haematoxylin for 15 
seconds, dehydrated in graded ethanol washes, and mounted in DPX (Lamb, 
Eastbourne, United Kingdom).  
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RESULTS 
Temporal expression (quantitative RT-PCR) 
All investigated factors were expressed from 13.5 weeks gestation onwards to term, and 
in adults. In figure 4.1, the relative mRNA expression of each of the 6 factors investigated 
is depicted for each of the developmental stages and in the adult lung. Although there 
are reciprocal trends in the expression of HIF-2α and HIF-3α, with the former showing an 
increase throughout pregnancy and the latter showing a decrease, this does not reach 
statistical significance. However, there is a clear increase in the expression of VEGF-A 
near the end of pregnancy, i.e. in the alveolar phase, which is also apparent in adult 
lungs (P < 0.01 for alveolar or adult phase vs. pseudoglandular, canalicular, or saccular 
phase). No obvious increase or decrease in the expression of VHL, HIF-1α, or VEGFR-2 
can be seen. 
 
When the expression levels of all individual fetal samples are plotted against gestational 
age, HIF-2α and VEGF-A show a positive correlation in the course of fetal lung 
development (HIF-2α: r = 0.249, P = 0.023; VEGF-A: r = 0.587, P < 0.01) (Figure 4.2).  
 
 
 
 
Figure 4.1 mRNA expression of VHL, VEGF-A, VEGFR-2, HIF-1α, HIF-2α, and HIF3-α in human 
lungs. Samples were grouped according to their developmental stages i.e. Pseudoglandular (Pseu), 
Canalicular (Can), Saccular (Sac), Alveolar (Alv) and Adult (Ad); n = 5 per group. Data are shown as 
mean 2-∆∆Ct ± SEM (as outlined in Materials and Methods). VEGF-A expression is significantly higher 
in the alveolar stage and in adult (*, P < 0.01). There was no significant difference in mRNA 
expression in other genes (P > 0.05).
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Figure 4.2 Positive correlation between HIF-2α and VEGF-A mRNA expression and gestational age 
of 20 samples from 13.5 to 41 weeks of gestation. The r-values show Spearman's correlation 
coefficient with gestational age.  
 
Immunohistochemistry for HIF-1α and HIF-2α 
The immunostaining for HIF-1α and HIF-2α revealed that both subunits were expressed 
in all tissues examined. HIF-1α immunoreactivity was primarily detected in the airway 
epithelium and showed a consistent pattern throughout gestation (Figure 4.3a-d). HIF-2α 
reactivity was detected mainly in the interstitium at early stages of lung development 
(Figure 4.4a, b), whereas its expression in the airway epithelium, predominantly in type II 
pneumocytes, was detected later on the gestation (Figure 4.4c, d). 
 
 
DISCUSSION 
In this study, we analyzed the expression of factors involved in the VHL-HIF-VEGF 
pathway during human lung development. Our quantitative PCR data demonstrated that 
VHL, HIF-1α, HIF-2α, HIF-3α, VEGF-A and VEGFR-2 are expressed in human lung 
tissue from 13.5 weeks of gestation onwards. Moreover, HIF-2α and VEGF-A mRNA 
expressions increase with advancing gestation. Immunohistochemistry was performed to 
show sites of HIF-1α and HIF-2α expression. HIF-1α expression was consistently 
detected in the airway epithelium throughout gestation. HIF-2α expression was first 
detected in the interstitium, while later on in gestation its expression was detected in type 
II pneumocytes. The sites of expression of VHL and VEGF were shown in our previous 
work.19 
 
Chapter 4 
 50 
  
Figure 4.3 (for color figures see page 108) HIF-1α immunostaining with strong expression in airway 
epithelium of human fetal lung at different gestational ages; (a) 16 wk, (b) 21 wk, (c) 27 wk, and (d) 31 
wk. (Magnification, X 400) 
 
  
Figure 4.4 (for color figures see page 109) HIF-2α immunostaining with predominant reactivity in the 
interstitium at early stages of human fetal lung development; (a) 16 wk, (b) 21 wk. Later on in 
gestation, HIF-2α expression was also detected in type II pneumocytes; (c) 27 wk, and (d) 33 wk. 
(Magnification, X 400) 
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The intimate relationship between the pulmonary vasculature and the airways suggests 
that these two systems interact during development. Recent reports have indeed 
indicated an essential role for vascularization in airway development.2-4,21 In utero 
pulmonary development occurs in a relatively hypoxic environment and one of the most 
potent angiogenic factors, VEGF-A, is actively transcribed under hypoxic conditions. 
VEGF-A transcription is upregulated in a hypoxic environment by one of oxygen sensitive 
HIF subunits.22-24 Our PCR data showed a positive correlation between gestational age 
and mRNA expressions of HIF-2α and VEGF-A. The mRNA expressions of HIF-1α and 
HIF-3α do no significantly change during fetal lung development. These results are 
compatible with previous studies in mouse lungs that showed increased expressions of 
HIF-2α and VEGF during development, whereas HIF-1α expression remained 
constant.18,22 Animal studies have shown that HIF-2α deficiency and the lack of VEGF in 
later stages of lung development result in impaired lung maturation and insufficient 
surfactant production.18 Using immunohistochemistry, we demonstrated that HIF-1α is 
mainly expressed in the bronchial epithelium throughout gestation, whereas HIF-2α is 
predominantly expressed in the interstitium in earlier stages and appears in the 
epithelium later in development. The expression of HIF-2α in the airway epithelial cells is 
in agreement with previous reports demonstrating HIF-2α expression in type II 
pneumocytes in mouse lungs.18,22 The difference in the expression patterns between 
HIF-1α and HIF-2α may reflect their individual roles in lung development.  
 
HIF-1α and HIF-2α share a high degree of structural and functional similarity as 
emphasized by their ability to interact with hypoxia response elements of the target 
genes and the subsequent induction of transcriptional activity.14 However, ample 
evidence suggests that these two alpha subunits also have distinct physiologic roles. 
While HIF-1α is ubiquitously expressed, HIF-2α transcripts are more restricted to 
particular cell types, for instance vascular endothelial cells, type II pneumocytes and liver 
parenchyma.16,18,22,25 Analysis in embryonic stem cells suggested that HIF-1α, but not 
HIF-2α, plays an important role in hypoxia responses.15,26,27 In contrast to the stem cells 
studies, HIF-2α has been shown to be crucial in stimulating several hypoxia-inducible 
genes (including tyrosine hydroxylase and VEGF) during embryonic development.16-18 
Moreover, a growing number of differences between HIF-1α and HIF-2α with respect to 
cell-specific regulation, hypoxic and non-hypoxic stimuli, interaction partners, and 
downstream targets is being reported.27-31 In animal studies, HIF-1α-/- mice exhibit 
midgestational lethality with severe blood vessel defects.15 Although homozygous HIF-2α 
knockout embryos also showed a defect in vascular remodeling, with aberrant vascular 
formations,17 a subset of the offspring survived to term but suffer from respiratory 
distress due to surfactant insufficiency.16-18 
 
A third HIF protein, HIF-3α, is also able to dimerize with HIF-1β and binds to hypoxia 
response elements. Among several splice variants of HIF-3α, inhibitory PAS domain 
protein (IPAS) is the best characterized. In adult mice under normoxic conditions, IPAS is 
predominantly expressed in Purkinje cells and corneal epithelium. However, IPAS can 
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also be induced by hypoxia in the heart and lung. In contrast to the role of HIF-1α and 
HIF-2α, IPAS has no endogenous transactivation function and has been reported to act 
as a dominant negative regulator of HIF-1α.24,32 
 
The VEGF signaling pathway has been shown to play a crucial role in embryonic 
vasculogenesis, particularly during fetal lung development.8,10-12 The level of VEGF is 
critical for normal lung development. Overexpression of VEGF in distal lung altered 
vascularization and arrested airway branching,8 whereas a decrease in lung VEGF 
resulted in poor septal formation and an emphysematous pattern.33 In addition, reduced 
VEGF levels in tracheal aspirates were also observed in infants with bronchopulmonary 
dysplasia.34,35 
 
It has been shown that the VEGF-pathway is important for both vascular development 
and branching morphogenesis.5,6,36 The roles of VEGF-A and its receptors in lung 
development were anticipated by their expression patterns. VEGF–A is expressed mainly 
in the epithelial cells,37 whereas VEGFRs are expressed in the mesenchymal cells. 
VEGF-A is also detected in alveolar type 2 cells and has an effect on the synthesis of 
surfactant protein (SP). VEGF-treated human lung explants demonstrated increased SP-
A and SP-C mRNA compared with control lungs (38). Furthermore, VEGF could rescue 
HIF-2α+/- mice, which showed defective surfactant production, alveolar septal vascular 
defects and respiratory distress at birth.18 Our finding of increasing VEGF-A mRNA 
expression in fetal human lung during development suggests that the role of VEGF-A is 
not restricted to the initial phase of pulmonary development. Previous studies in VEGF-A 
knock-out mouse embryos have shown that VEGF-A is also necessary for events later in 
gestation such as vessel sprouting and maintenance of vessel integrity.39,40 
 
It appears that VEGFR-2 is the main receptor mediating the effect of VEGF-A on lung 
maturation. The study by Compernolle and colleagues in mice with antibodies against 
VEGFR-1 and VEGFR-2 indicates that only VEGFR-2 mediates the effects of 
endogenous VEGF on lung maturation in vivo.18 Thus far, there are limited data on the 
ontogeny of VEGFR-2 in human lung development. In this study, we demonstrated no 
significant change of VEGFR-2 mRNA expression during human fetal lung development.  
 
Taken together, we have shown that hypoxia-inducible factors, particularly HIF-2α, 
appear to exert an important role in vascular growth and airway branching 
morphogenesis in human fetal lung, especially in the last phases of pregnancy. The 
suggestive anti-correlation between HIF-2α and HIF-3α indicates a putative important 
regulatory role. This action occurs by regulation from interstitial and epithelial cells 
through an effect on downstream target genes, such as VEGF-A. These data contribute 
to our basic knowledge about normal pulmonary (vascular) development and may serve 
as a reference for the interpretation of pathological states such as primary pulmonary 
hypertension and congenital diaphragmatic hernia. 
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ABSTRACT 
Many investigations suggest that fetal lung development requires proper coordination 
between lung epithelial and vascular morphogenesis. A major determinant in lung 
vascular development is vascular endothelial growth factor (VEGF), which is regulated 
by hypoxia-inducible factors (HIFs). While VEGF expression is limited to airway 
epithelium, its receptors are expressed in pulmonary mesenchyme. Relatively low 
oxygen environment in utero is beneficial for fetal organogenesis, especially vascular 
development. Herein, we used a fetal human lung explant culture model to investigate 
the effects of hypoxia on fetal lung morphology and the mRNA expressions of VEGF, 
VEGFR-2, HIF-2α, and HIF-3α. The morphology remained largely unchanged in explants 
cultured at hypoxia compared with explants cultured at normoxia, and cell specific 
markers confirmed the viability of the explants after culturing for 6 days. Quantitative 
PCR showed that the mRNA expression of VEGF-A, but not VEGFR-2 is upregulated in 
explants cultured at 1.5% oxygen compared with 20% oxygen. We observed slight 
increases in HIF-2α and HIF-3α mRNA expressions in explants cultured at 1.5% oxygen 
compared with 20% oxygen; however the differences are not significant. These data 
suggest that the expression of VEGF and possibly that of HIF-2α is regulated by hypoxia 
in the developing human lung. Human lung explant culture appears to be a valuable 
model to unravel the molecular mechanism of factors that are known to modulate human 
lung development such as steroid hormones and retinoic acid.  
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INTRODUCTION 
The molecular basis of pulmonary development has been studied extensively over the 
past few decades. Many morphogens, growth and transcription factors have been shown 
to play key roles in different stages of fetal lung development.1-3 Pulmonary development 
is a sophisticated process requiring reciprocal interactions between epithelium and 
mesenchymal cells. Accumulating evidence underlines the importance of vascular 
development to distal airway growth and development.4-6 It is important to note that 
normal pulmonary development occurs in a relatively hypoxic environment. A number of 
studies have shown that the relatively low oxygen environment of the fetus is favorable 
for embryo development and organogenesis.5,7-9 
 
The cellular responses to oxygen alteration in most mammalian systems are mediated by 
hypoxia-inducible factors (HIFs), which are known to control more than 100 genes.10 The 
HIF transcriptional complex is a heterodimer composed of one of the three oxygen-
sensitive alpha subunits (HIF-1α, HIF-2α, or HIF-3α) and the constitutive beta subunit 
(HIF-1β/ARNT).11,12 Under hypoxic conditions, the HIF heterodimer accumulates in the 
nucleus and binds to hypoxia response elements of target genes, thereby regulating their 
transcription. In normoxia, hydroxylation of HIF-α subunit by prolyl hydroxylases (PHDs) 
mediates interactions with the von Hippel-Lindau protein (pVHL), which subsequently 
leads to its ubiquitination and targets HIF-α for proteasomal destruction.11,13  
 
One of the most potent hypoxia-inducible growth factors is vascular endothelial growth 
factor-A (VEGF-A). VEGF-A signals through two high affinity tyrosine kinase receptors, 
VEGFR-1 (Flt-1), and VEGFR-2 (KDR in human or Flk-1 in mouse). In the lung, VEGF-A 
functions as a mitogen and differentiation factor for endothelial cells.14 While VEGF-A is 
expressed mainly in the epithelial cells of the lung,15 VEGFRs are expressed in the 
mesenchymal cells. The level of VEGF is critical for normal lung development. 
Overexpression of VEGF in distal lung alters vascularization and arrests airway 
branching,16 whereas inhibition of VEGF results in less complex alveolar patterning and 
immature lung formation.17 The evidence that homozygous null VEGFR-2 mice die in 
utero as a result of a lack of mature endothelial cells and absence of blood island 
formation, suggests a role of VEGFR-2 in mediating the mitogenic and chemotactic 
effects of VEGF-A on the endothelial cells.18 
 
In vitro studies using rat lung explants cultured at 3% oxygen showed an increase in 
epithelial branching and cellular proliferation.9 Previous studies in transgenic mouse 
lungs showed the increase of both epithelial and endothelial branching morphogenesis in 
explants cultured at 3% oxygen compared with 20% oxygen. Additionally, by using 
antisense oligonucleotides against HIF-1α and VEGF, our group previously 
demonstrated that epithelial branching morphogenesis is drastically abolished when 
pulmonary vascular development is inhibited.5 
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Based on the aforementioned information, a low oxygen environment of the fetus seems 
critical for pulmonary angiogenesis and possibly airway branching morphogenesis. 
Human lung explants maintained in vitro were used in a number of studies on lung 
development. For instance, Acarregui et al. previously showed the effect of low oxygen 
and cAMP on VEGF mRNA expression.15 However, very little data are available 
regarding the expressions of HIF-2α, HIF-3α and VEGFR-2 in human fetal lung. In this 
study we therefore used human fetal lung explants maintained in vitro to study the 
influence of low oxygen tension on the expressions of HIF-2α, HIF-3α, VEGF-A, and 
VEGFR-2 in the developing human lung. 
  
 
MATERIALS AND METHODS 
Lung tissues and explants culture 
Lung tissues were obtained from human abortuses of 16 to 22 weeks of gestation, 
following the approval of the Erasmus MC Ethical Review Board of the experimental 
design and protocols and informed consent from the pregnant women. Fetal lung tissue 
was carefully separated from major blood vessels and airways, and dissected into 1 to 2 
mm3 pieces. Lung explants (2 - 3 pieces) were placed on Nucleopore membranes (pore 
size 8µm; Whatman, Den Bosch, Netherlands), and incubated as air-liquid interface 
cultures in serum-free Waymouth’s MB752/1 medium (GIBCO, Breda, Netherlands) with 
1% Penicillin-Streptomycin and 1% Insulin-Transferrin-Selenium (GIBCO). Tissues were 
maintained either under standard culture incubator conditions of 37°C and 5% CO2/ 95% 
air (20% oxygen; normoxia), or in an incubator with 1.5% O2, 5% CO2, and 93.5% N2 
(hypoxia). The culture medium was changed every 24 hours and tissues were harvested 
after 3 or 6 days of culture in normoxia or hypoxia. 
 
Immunohistochemistry 
Immunohistochemistry was performed using a standard avidin-biotin complex method. In 
brief, after deparaffinization for 10 min in xylene and rehydration through graded alcohol, 
slides were treated with 3% H2O2 in methanol to block the endogenous peroxidase 
activity. For antigen retrieval, slides were subjected to microwave treatment in citric acid 
buffer, pH 6.0 (Ki-67, TTF-1) or pronase (CD-31). After the blocking step, slides were 
incubated for 30 min at room temperature with a primary antibody against Ki-67 (1:150, 
Dako, Heverlee, Belgium), TTF-1 (1:100, Ab-1, Neomarkers, CA, USA), or CD-31(1:30, 
clone MIB-1, Dako). After rinsing with PBS, slides were incubated for 10 min with a 
biotinylated secondary antibody (Labvision, CA, USA), followed by 10 min incubation 
with peroxidase-conjugated streptavidin (Labvision). Peroxidase activity was detected by 
diaminobenzidine tetrahydrochloride (Fluka, Buchs, Switzerland) with 0.3% H2O2 and 
counterstained with hematoxylin. Negative controls were replicated by omission of the 
primary antibodies. 
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RNA isolation and quantitative RT-PCR 
RNA from uncultured lung tissue and explants that had been cultured for 3 and 6 days 
were used for quantitative PCR analysis. Total RNA was isolated using Trizol reagent 
(Invitrogen, Breda, Netherlands) according to the manufacturer’s instructions. RNA was 
quantified by measuring the absorbance at 260 nm and the purity was checked by the 
260/280 nm absorbance ratio. Total RNA (1 µg) was added to a reaction mixture 
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 100 
ng random hexamer primer, 500 µM of each deoxynucleotide triphosphate (dATP, dGTP, 
dCTP and dTTP), 10 U RNAse inhibitor and 200 U Moloney Murine Leukaemia Virus 
Reverse transcriptase (all reagents were obtained from Invitrogen). The RT thermal cycle 
was 1 hour at 37 °C followed by incubation for 15 min at 99°C. 
 
Real-time PCR was performed using an iCycler IQ Real time PCR detection system (Bio-
Rad, Veenendaal, The Netherlands) and qPCR Core kit for SYBR Green I (Eurogentech, 
Seraing, Belgium) under the following conditions: 10 min of initial denaturation at 95°C 
followed by 40 cycles of 95°C for 30 s, 58°C for 30 s, 60°C for 30 s, and 75°C for 15 s. 
The sequences for gene-specific primers used in this study are described previously in 
Chapter 4. To verify the specificity of the amplified products, each PCR was followed by a 
melting curve analysis from 55°C to 95°C. Each sample was run as a triplicate and 
mRNA of each target gene was determined simultaneously in a 96-wells plate. Negative 
(no enzyme) and no-template (no cDNA) controls were also included. 
 
For the relative quantitation, PCR signals were normalized using RNA Polymerase II, 
Subunit A (POLR2A) as an internal reference. The fold change was calculated as 2-∆∆Ct 
according to Livak and Schmittgen.19 Lung tissue from day 0 (starting material) was used 
as a control group (arbitrary value = 1). 
 
Statistical analysis 
Data from the quantitative PCR are presented as mean 2-∆∆Ct ± SEM. The differences 
between experimental groups were evaluated by using one-way ANOVA with post hoc 
least significant difference test. P < 0.05 was considered statistically significant. All 
statistics were calculated using SPSS statistical package (version 11.0; SPSS Inc., 
Chicago, IL). 
 
 
RESULTS 
Morphology of human fetal lung explants cultured at 20% oxygen 
To evaluate the feasibility of fetal lung explants maintained in vitro under our conditions, 
human fetal lung explants derived from mid-trimester abortuses were maintained at 20% 
oxygen for 6 days. The microscopic appearance of the explants after culturing for 3 and 
6 days (Figure 5.1B and C respectively) resembled the pseudoglandular stage of lung 
development (Figure 5.1A); except that the airways were dilated and the epithelial cells 
appeared flattened. 
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Figure 5.1 (for color figures see page 110) Morphology of human fetal lung explants cultured at 20% 
oxygen. Hematoxylin & Eosin staining of uncultured lung (A) resembled the pseudoglandular stage of 
lung development. The airways were dilated after the explants were cultured for 3 (B) and 6 days (C) 
at 20% oxygen. Bar, 500 µm. 
 
To evaluate cell differentiation characteristics of the explants, immunohistochemistry with 
markers for epithelial cells (TTF-1), endothelial cells (CD-31) and proliferation (Ki-67) 
was performed on sections of explants cultured for 3 and 6 days. There was no 
difference in expression patterns of all markers between uncultured lungs and explants 
cultured for 3 or 6 days at 20% oxygen. Virtually all epithelial cells are positive for TTF-1 
staining (Figure 5.2A, D, G), whereas endothelial cells are positive for CD-31 (Figure 
5.2B, E, H). Ki-67 immunoreactivity was observed in both epithelial and mesenchymal 
cells (Figure 5.2C, F, I). Double immunohistochemical staining with Ki-67 and CD-31 
showed ongoing endothelial proliferation in the explants cultured at normoxia after 6 
days in culture (Figure 5.3B).  
 
Morphologic changes associated with hypoxic exposure of fetal lung explants  
Lung sections were immunostained with Ki-67, TTF-1 and CD-31 after the explants had 
been cultured for 6 days at either normoxic or hypoxic conditions, and uncultured tissue 
was used as control. The airways were larger in both hypoxic and normoxic cultured lung 
at day 6 compared with control. There were no differences in the localization of TTF-1 
(Figure 5.2G, J) and CD-31 (Figure 5.2H, K) between explants cultured at 20% and 1.5% 
oxygen. However, CD-31 immunoreactivity appeared to be stronger in hypoxic-exposed 
lung compared with explants cultured at normoxia (Figure 5.2K vs. 5.2H). A proliferation 
marker, Ki-67, was expressed in both epithelium and mesenchymal cells in control and 
explants cultured at 20% oxygen (Figure 5.2C, F, I) but appeared to be more restricted to 
the epithelium in explants cultured at 1.5% oxygen (Figure 5.2L) 
 
Quantitative RT-PCR 
Quantitative PCR showed that VEGF-A, VEGFR-2, HIF-2α, and HIF-3α mRNA were 
expressed in all experimental groups (n = 5 per group). The relative mRNA expression of 
each gene is shown as mean ± SEM in Figure 5.4. There was an increase in VEGF-A 
mRNA expression in explants cultured at 1.5% oxygen compared with explants cultured 
at 20% oxygen and control (P ≤ 0.01). However, under hypoxic conditions, VEGF-A 
mRNA expression was downregulated in explants cultured for 6 days compared with 3 
days (P < 0.01). There was no significant change in the expression of VEGFR-2 between 
the explants cultured in normoxia and hypoxia. Although mRNA expression of HIF-2α 
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(day 3) and HIF-3α (day 6) was slightly higher in the explants cultured at 1.5% oxygen 
compared with explants cultured at 20% oxygen, the difference did not reach statistic 
significance. 
 
 
Figure 5.2 (for color figures see page 111) Immunohistochemical staining with TTF-1, CD-31, and 
Ki-67 of uncultured lung (A-C), explants cultured at 20% for 3 (D-F) or 6 days (G-I), and 1.5% oxygen 
for 6 days (J-L). TTF-1 immunoreactivity is detected in epithelial cells (A, D, G, J). Explants cultured at 
1.5% oxygen (K) showed stronger CD-31 staining in the endothelial cells compared with control (B) 
and explants cultured at 20% oxygen (E, H). Ki-67 staining (C, F, I, L) showed proliferating epithelial 
cells and mesenchymal cells in control (C) and explants kept at 20% oxygen (F, I), whereas the 
expression is more restricted to mesenchyme in explants kept at 1.5% oxygen (L). Bar, 500 µm. 
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Figure 5.3 (for color figures see page 112) Double immunostaining of Ki-67 and CD-31 on explants 
cultured at 20% oxygen for 6 days. Ki-67 (A) immunoreactivity is detected in epithelium and 
mesenchyme. Double staining with CD-31 (pink staining) shows proliferating endothelial cells (arrows; 
B). Bar, 250 µm. 
 
 
Figure 5.4 Relative mRNA expression of VEGF-A, VEGFR-2, HIF-2α, and HIF-3α in human fetal 
lung explants maintained for 3 or 6 days in 20% oxygen (Nd3 and Nd6, respectively) or 1.5% oxygen 
(Hd3 and Hd6, respectively) and uncultured lungs (d0). Bar represent means ± SEM (n = 5). VEGF-A 
mRNA expression is upregulated in explants cultured at 1.5% oxygen (Hd3 and Hd6) compared with 
explants cultured at 20% oxygen (Nd3 and Nd6) and control (d0) but its expression in explants kept at 
hypoxic conditions declines when cultured for a longer period (Hd6 vs. Hd3). * P ≤ 0.01 vs. d0, Nd3, 
and Nd6. # P < 0.01 vs. Hd3. 
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DISCUSSION 
The developing lung requires the formation and maintenance of a vascular network in 
close proximity to a layer of alveolar epithelial cells. In this study, we demonstrated that 
human lung explants cultured for 3 to 6 days at 1.5% oxygen maintain appropriate 
proliferation and differentiation of the airway epithelium as well as endothelial cells. 
Moreover, we demonstrated that VEGF-A mRNA expression was increased in the 
explants cultured under hypoxic conditions. There were no significant changes in the 
mRNA expressions of VEGFR-2, HIF-2α, and HIF-3α.  
 
Maintaining oxygen homeostasis is essential for tissue development, growth, and 
preservation of structural integrity. Normal fetal development takes place in a relatively 
hypoxic environment and hypoxia is known to be an important regulator of angiogenesis. 
Fetal lung explants maintained in vitro are a well-characterized model for studying fetal 
lung development. The differentiation of midgestational human fetal lung explants in 
culture has been characterized both biochemically and morphologically as represented in 
table 5.1, which contains an overview of the difference studies published.15,20-27 For 
instance, the distal epithelium of human fetal lung tissues differentiates spontaneously 
into type II pneumocytes in an atmosphere of 20% oxygen.20 However, there is little 
information on the role of hypoxia at the cellular level in embryonic lung development. 
Previous studies in murine lungs have shown that hypoxia, relative to ambient oxygen 
condition, enhances the development of pulmonary vasculature and airway epithelial 
branching morphogenesis.5,9 In the present study we observed that the airway epithelium 
explants appeared flattened within the dilated airspace after being maintained at 1.5% 
oxygen for 6 days. The immunohistochemical studies with epithelium and endothelium 
specific markers showed no obvious differences in the localization of TTF-1 and CD-31 
between human lung explants cultured at 1.5% oxygen or 20% oxygen. Ki-67, a 
proliferation marker, showed that cells in the lung explants maintain their character and 
are still dividing. A formal quantification of the proliferating cells was not performed. 
 
The close anatomical relationship between airways and blood vessels in the lung 
suggested their putative interaction during development. The inhibition of vascularization 
in mouse lungs in vitro resulted in a decrease in epithelial branching morphogenesis.5 In 
addition, Schwarz et al. showed that inhibition of vascular development with endothelial 
monocyte activating polypeptide II (EMAPII) resulted in an inhibition of airway epithelial 
morphogenesis.28 Many studies have provided evidence that VEGF acts as a potent 
inducer of endothelial cell growth and that hypoxia is one of its important stimuli.14,15 
VEGF is essential for embryonic development as it was shown that inactivation of a 
single VEGF allele results in embryonic lethality with impaired vessel formation.14,29 In 
this study, we showed that VEGF-A mRNA expression is significantly upregulated in lung 
explants cultured at 1.5% oxygen for 3 and 6 days as compared to explants cultured at 
normoxic conditions. Similar findings have been reported for VEGF expression in 
human,15 mouse,5 and rat9 fetal lung explants cultured at low oxygen. These results 
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confirm that low oxygen stimulates VEGF expression and possibly vascular development 
in lung explants. 
 
While VEGF has been detected mainly in the distal epithelium of the fetal lung and its 
expression increases as the lung develops,15,30 its receptors are strongly expressed in 
the mesenchyme.4,6 VEGF and its receptors being expressed in adjacent tissues suggest 
a signaling loop between these two components during lung development. It has been 
shown that VEGF-A signaling through VEGFR-2 is important not only for vasculogenesis 
but also for triggering an increase in pulmonary epithelial morphogenesis.6,31 The 
VEGFR-2 blocker SU-5416 causes a decrease in capillary density and inhibits septation, 
leading to lung immaturity.32 VEGFR-2 expression has been shown to be stimulated by 
HIF-2α33 but no oxygen-dependent upregulation of VEGFR-2 expression in human lung 
has been reported. Previous studies in a transgenic mouse model showed that after two 
days’ culture VEGFR-2 mRNA expression was increased in mouse lung explants 
cultured under hypoxic conditions compared to explants cultured under normoxic 
conditions. However, when the explants were cultured for a longer period, this significant 
difference was no longer noticeable.5 Our results showed no difference in VEGFR-2 
mRNA expression in human lung explants cultured for 3 or 6 days at 1.5% oxygen 
compared with explants cultured at 20% oxygen. Together with findings from previous 
studies in mice, these results suggest that the effect of hypoxia on VEGFR-2 mRNA 
expression is transient. 
 
VEGF gene transcription is activated by hypoxia through hypoxia-inducible transcription 
factors.34-36 HIF-1α and HIF-2α have a close sequence similarity but their modes of 
expression vary greatly. HIF-2α was reported to be abundantly expressed in murine adult 
lungs under normoxic conditions.34,37 Although HIF-2α-null mice exhibit embryonic 
lethality with abnormal lung maturation and blood vessel defects38 or a defect in 
catecholamine production,35 a subset of HIF-2α knockout offspring survived postnatally 
but suffered from respiratory distress due to surfactant deficiency.39 HIF-3α, which was 
discovered recently, appears to be involved in negative regulation of the angiogenic 
response through an alternative splice variant, inhibitory PAS domain protein (IPAS).40 
IPAS can be induced by hypoxia in heart and lung resulting in a negative feedback loop 
for HIF-1α activity in these tissues.41 To date very little data are available regarding the 
expression and function of HIF-3α. A previous study in adult mice by Heidbreder et al. 
reported that mRNA expression of HIF-3α, but not HIF-2α increased significantly 
corresponding to the duration of systemic hypoxia. In addition, they found an increase in 
both HIF-2α and HIF-3α protein levels.37 Our quantitative PCR show a slightly increase in 
HIF-2α mRNA expression in explants cultured under hypoxic condition at day 3 but the 
difference is not significant. There is also no significant hypoxic induction of HIF-3α 
mRNA expression in human fetal lung explants. This can be explained by the fact that 
HIF expression is mainly regulated at the posttranslational level.13 However, in 
combination with our observation that VEGF-A, one of the prime targets for HIF-2α 
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transcription, is dramatically induced in the explants cultured at 1.5% oxygen, it appears 
that the hypoxic conditions induce HIF-2α expression as well.  
 
In summary, this study has demonstrated that fetal human lung explants exposed to 
relative hypoxia (1.5% oxygen) maintain proper epithelial and mesenchymal 
morphogenesis. The increase in VEGF-A expression under hypoxic conditions suggests 
a role for VEGF-A in regulating pulmonary vascular and airway development. Human 
fetal lung explants maintained in a serum-free system allowed us to focus on the local 
effects of oxygen tension rather than on a systemic response to hypoxia. This model can 
be applied to investigate the effects of different ligands that influence lung development, 
such as retinoic acid and steroid hormone. Moreover, this reproducible model of human 
embryonic lung cultures makes it possible to culture lungs under conditions of abnormal 
lung development, such as pulmonary hypoplasia resulting from obstructive uropathy 
and oligohydramnios, or congenital diaphragmatic hernia. 
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INTRODUCTION 
Newborns with congenital diaphragmatic hernia (CDH) may suffer from severe 
pulmonary hypoplasia and persistent pulmonary hypertension.1 Despite innovations in 
prenatal and postnatal care, mortality and morbidity in these patients remain high. The 
developing fetal lung undergoes dramatic tissue growth and remodeling to achieve the 
mature structure required for its postnatal role as an air-exchanging organ. 
Organogenesis of the lung is highly dependent on epithelial-mesenchymal interactions.2,3 
The fetal lung remains densely cellular after completion of bronchial branching during the 
pseudoglandular stage. An effective alveolar-capillary interface is then gradually 
established by regression of the mesenchyme, with simultaneous flattening of the 
epithelium and outgrowth of capillaries. This process begins in utero during the 
canalicular and saccular stages of lung development and is completed postnatally during 
the alveolar stage. 
 
Normal organogenesis requires a delicate balance between cell proliferation, cell 
differentiation, and cell death.4 Apoptosis, a form of programmed cell death, has been 
shown to be involved in several processes during embryogenesis, including involution of 
web space in limb bud development5 and kidney6 and heart development.7 Several 
regulatory genes affecting apoptosis have been identified, the most prominent being the 
Bcl-2 family. Apoptosis is initiated by translocation of pro-apoptotic Bcl-2 family members 
(e.g. Bax) and is prevented by overexpression of anti-apoptotic molecules such as Bcl-2 
or Bcl-XL.8 In view of the well-established role of apoptosis in embryonic and fetal 
modeling processes, we hypothesized that apoptosis may play a role in normal and 
abnormal lung development. Previous studies have suggested that apoptosis is involved 
in prenatal and postnatal lung remodeling as well.9,10 Pulmonary hypoplasia in CDH may 
be the result of disturbances in normal mechanisms of pulmonary organogenesis such 
as apoptosis and proliferation. In this study, therefore, we examined the expressions of 
proteins associated with activation (Bax) or inhibition (Bcl-2) of apoptosis in human CDH 
lungs. In parallel, we examined these lungs for cell proliferation by immunohistochemical 
identification of Ki-67 expression. 
 
 
MATERIALS AND METHODS 
Lung tissues 
Following approval of the experimental design and protocols by the Erasmus MC Ethical 
Review Board, lung tissues were retrieved from the tissue bank of the Department of 
Pathology, Erasmus MC, Rotterdam. We obtained 17 CDH lung samples collected from 
either termination of pregnancy or patients who died within 48 hours after birth 
(gestational age 18 - 41 weeks). None of these patients had been subjected to prenatal 
steroid or extracorporeal membrane oxygenation therapy postnatally. Lung tissue from 
20 fetuses and newborns (from termination of pregnancy or autopsies) without 
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pulmonary abnormalities served as control material (gestational age 13.5 - 41 weeks). All 
samples had been harvested within 24 hours after death. 
 
Immunohistochemistry 
Antibodies used were Ki-67 (clone MIB-1, 1:150, Dako, Heverlee, Belgium), Bax (1:200, 
Dako, Heverlee, Belgium), and Bcl-2 (clone 124, 1:100, Dako, Heverlee, Belgium). 
Immunohistochemistry was performed using a ChemMate™ DAKO EnVision™ Detection 
Kit, Peroxidase/DAB, Rabbit/Mouse (DakoCytomation B.V., Heverlee, Belgium). 
Immunohistochemical techniques are described in detail in our previous study.11 
Negative controls were performed by omission of the primary antibodies. 
 
 
RESULTS AND DISCUSSION 
In this study, we evaluated cell proliferation and expression of apoptotic related proteins 
during normal human lung development and in human CDH lungs. The proliferation 
marker Ki-67 was expressed in both airway epithelium and mesenchyme (Figure 6.1). 
Early in gestation, its expression was more prominent in epithelial cells, with a shift to the 
mesenchyme, however, later in gestation. Bcl-2 protein expression was detected in the 
basal layer of airway epithelium and mesenchymal cells in earlier stages of development 
(figure 6.2 A, B). Later in gestation its expression was also detected in airway epithelial 
cells (Figure 6.2 C-F). The pro-apoptotic protein Bax was detected in virtually all 
epithelial cells; moreover it was also detected in pulmonary artery endothelium (Figure 
6.3). The pattern of Bax protein expression remained unchanged throughout gestation. 
There were no striking differences in the expression patterns of Ki-67, Bcl-2, or Bax 
between normal and CDH lungs. The different levels of the pulmonary vascular tree 
showed no significant differences between control lungs and CDH lungs. Cell counts 
were not performed, because postnatal changes could be the result of therapy-related 
sequelae and postmortem degradation of tissue, making interpretation of the results 
difficult. 
 
Cell death in multicellular organisms occurs by either necrosis or apoptosis, each of 
which has distinct morphologic and biochemical characteristics. Cells undergoing 
apoptosis show shrinkage, nuclear condensation, and DNA fragmentation, but the 
cytoplasmic membrane remains intact during the early stage.12 Apoptosis is an active 
process and proceeds by a multistep cascade involving specific membrane receptors 
(such as Fas), the Bcl-2 proteins family, and cystein proteases (caspases).13 The 
presence of the signaling proteins for apoptosis in the developing lung in our study is not 
surprising because these proteins are constitutively expressed in many tissues and cell 
lines.4,14-16 The similar expression of Bcl-2 and Bax between normal and CDH lungs 
suggests that the disturbance of apoptosis in CDH lungs, if any, occurs largely 
independent of the Bcl-2/Bax pathway. 
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Normal              CDH  
 
 
Figure 6.1 (for color figures see page 113) Immunohistochemical study of Ki-67 in normal (A, C, E) 
and CDH (B, D, F) lungs at different gestational ages; 18 weeks (A, B), 23 weeks (C, D), and 35 
weeks (E, F). Ki-67 immunoreactivity was detected in both epithelial and mesenchymal cells.  
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Normal              CDH  
 
 
Figure 6.2  (for color figures see page 114) Immunohistochemical study of Bcl-2 in normal (A, C, E) 
and CDH (B, D, F) lungs at different gestational ages; 18 weeks (A, B), 23 weeks (C, D), and 39 
weeks (E, F). Bcl-2, one of the anti-apoptotic proteins, was detected in the basal layer of airway 
epithelium and mesenchymal cells earlier in development (A, B). Later in gestation its expression was 
also detected in airway epithelial cells (figure 2 C-F).  
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Normal              CDH  
 
 
Figure 6.3 (for color figures see page 115) Immunohistochemical study of Bax in normal (A, C) and 
CDH (B, D) lungs at different gestational ages; 23 weeks (A, B), 38 weeks (C, D). Bax 
immunoreactivity was strongly expressed in cytoplasm of airway epithelial cells. It was also detected in 
arterial endothelial cells. 
 
Apoptosis and lung development 
Organ development requires an orchestrated and complex interplay between 
proliferation, differentiation, and apoptosis.5,7,17,18 During organ morphogenesis, 
apoptosis occurs either by direct stimulation or by lack of growth and/or differentiation 
factors, resulting in the removal of unwanted or excessive cells. Although most of the 
organogenesis occurs in utero, the lung does not complete its development and 
maturation until after birth. In humans, alveolarization and microvascular maturation of 
the lung continues up to at least several years after birth. 
 
Apoptosis was first implicated in the process of lung development some ten years ago. It 
is observed in mesenchymal cells during the earlier stages of lung development,10 after 
which a shift takes place towards both mesenchymal and airway epithelial cells as from 
the canalicular stage onwards.9 Throughout embryonic lung development, apoptosis is 
almost exclusively found in the peripheral mesenchyme – in regions of new bud 
formation - or in the mesenchyme underlying branch points – the sites of extensive 
epithelial branching morphogenesis and remodeling of interstitial tissue, allowing room 
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for outgrowth of the lung bud.9,19 Interestingly, mesenchymal cells undergoing apoptosis 
were intermingled with proliferating mesenchymal cells,19 suggesting that coordination of 
these two processes is important in the cell dynamics associated with bronchial 
branching. One of the mechanisms believed to be involved in regulation of apoptosis 
during lung development is cellular stretch by mechanical force through liquid secretion 
or fetal breathing movements.20,21 
 
A delicate balance between apoptosis and proliferation is necessary to support a growing 
lung and to create room for growth early in gestation. Epithelial apoptosis becomes more 
important later in gestation with alveolar growth and seems to be stimulated in utero by 
increasing fetal breathing movements and postnatally by airway distension. 
 
In rabbits, normal fetal lung development was found to be associated with progressively 
increasing epithelial and mesenchymal apoptotic activity. This process is enhanced by 
tracheal ligation.22 Tracheal occlusion (TO) in utero is known to accelerate fetal lung 
development and was used in selected CDH cases to enhance lung growth and 
maturation before birth.23 De Paepe et al. demonstrated that synchronous to the onset of 
TO-induced distension and alveolar type 2 cell apoptosis, pulmonary FasL protein levels 
were dramatically higher in TO fetuses, whereas the expressions of Bcl-2 and Bax were 
similar in control and TO lungs at all time points.16 
 
Previous studies in the Nitrofen-induced rat model of CDH suggested a putative role of 
proliferation and apoptosis in both diaphragm and fetal lung development. While 
enhanced apoptosis was observed in cervical somites that were considered the 
precursors of the diaphragm,24 decreased proliferation was observed in Nitrofen-exposed 
lungs before diaphragmatic closure.25 In our studies in human material, no striking 
differences in cell proliferation between normal and CDH lungs were observed, although 
no quantitative analysis was performed. We cannot exclude that differences might have 
become apparent at earlier stages of lung development, for which, however, no human 
sample was available. Future animal experiments and human data might reveal the 
relevance of these studies for further insight into the role of proliferation and apoptosis 
during lung development in CDH cases. So far, diminished proliferation or disturbed 
balance due to increased apoptosis could not be proven. 
 
Role of apoptosis in development of pulmonary vascular remodeling 
Lungs of CDH patients are physically smaller than normal lungs, have fewer airway 
branches and show vascular abnormalities such as medial hyperplasia of the pulmonary 
arteries, adventitial thickening, and reduced size of the pulmonary vascular bed.26,27 
Under normal circumstances, apoptosis has important pathophysiological consequences 
contributing to the loss of pulmonary smooth muscle cells and therefore in lowering the 
pulmonary pressure.28-30 In recent years, the process of programmed cell death has 
gained more interest because of its influence on many pathological states. Increased 
proliferation and decreased apoptosis of pulmonary artery smooth muscle cells could 
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concurrently mediate thickening of the pulmonary vasculature, which subsequently 
reduces the luminal diameter of pulmonary arteries, increases pulmonary vascular 
resistance, and raises pulmonary arterial pressure.28,29,31 The balance between apoptosis 
and cell proliferation is vital for cellular homeostasis. Little is known, however, about the 
mechanism that coordinates these two processes, particularly in the vessel wall. The role 
of apoptosis in the pathogenesis and treatment of pulmonary hypertension was recently 
reviewed by Gurbanov and Shiliang.30 They concluded that smooth muscle cells 
apoptosis is a major feature of blood vessels remodeling and could be a target for new 
therapeutic approaches for patients with pulmonary hypertension. 
 
With regard to the pulmonary vascular abnormalities in CDH, the medial hyperplasia 
cannot be explained as the result of a disturbance between proliferation and apoptosis. 
Ongoing investigations are directed at unraveling the question whether persistence of 
subpopulations of pulmonary arterial smooth muscle cells contributes to this 
phenomenon. 
 
In conclusion, modulation of protein expression in the apoptotic cascade and evidence of 
ongoing cell proliferation during gestation suggest that the lung develops through a 
coordinated process of cell proliferation coupled with programmed cell death for 
structural remodeling. Recently our group indeed showed significant changes in matrix 
metalloproteinases and inhibitors thereof in CDH lungs and control lungs.32 While the 
role of apoptosis in many human diseases has been widely studied, little is known about 
altered patterns of apoptosis in numerous biologic and clinical fields, including pediatric 
surgery. The role of apoptosis and proliferation in pulmonary epithelial and vascular 
remodeling needs further investigation to define the mechanism involved in programmed 
cell death. 
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INTRODUCTION 
Congenital diaphragmatic hernia (CDH) has an incidence of 1 in 2500 live births and 
accounts for approximately 8% of major congenital anomalies.1 Effective treatment 
remains one of the major challenges for obstetricians, neonatologists, and pediatric 
surgeons for various reasons: the diversity of the clinical presentation, the amount of 
respiratory insufficiency, and the variability of pulmonary hypertension.2,3 The past two 
decades have seen rising numbers of cases diagnosed antenatally. At the same time, 
greater understanding of the pathophysiology of this condition was reached from insights 
gained in animal models of CDH and observational clinical studies. Several types of 
interventions in utero have been proposed to address CDH, but these efforts have met 
with variable success and are currently applied in very few institutions under 
experimental protocols for which informed consent is warranted.4,5 Despite improved 
clinical care of infants with CDH, the overall mortality rate for live born infants remains 
above 30% and is even higher if all prenatally identified fetuses are included.6,7 
Importantly, there is also significant morbidity among the CDH survivors, including 
developmental delay, gastroesophageal reflux, growth failure, and chronic pulmonary 
disease. This group of patients therefore requires long-term follow up.8 
 
The unpredictable response to postnatal treatment has led to the idea that correcting the 
defect and/or promoting lung growth prenatally might increase survival and bring down 
morbidity of infants with CDH – and thus would be the ultimate therapeutic goal. This 
strategy nevertheless requires better understanding of the mechanism(s) controlling lung 
development in CDH. Most current therapeutic recommendations are based primarily on 
observational studies and integration from findings of animal studies in clinical practice. 
The results from animal studies need to be further evaluated, however, before 
application for clinical use in CDH patients is feasible. This calls for setting up properly 
designed trials with enough power. 
  
 
PHARMACOLOGICAL MODULATION OF LUNG GROWTH 
As the benefit of fetal surgical intervention in utero remains unclear, pharmacological 
approaches to stimulate prenatal lung growth and maturation have been considered as 
an alternative strategy to improve the outcome in children with CDH. Several hormones 
studied in a variety of animal studies are suggested to effect lung maturation. 
Glucocorticoids and thyroid hormones seem to be the most important candidates for 
clinical practice. Morphological similarities between the lung of premature newborns and 
infants with CDH have led to the hypothesis that antenatal glucocorticoids (GC) might 
have beneficial roles.9,10 Moreover, changes in thyroid hormone metabolism are thought 
to be involved in the pathogenesis of Nitrofen-induced CDH in rats.11,12 Prenatal 
administration of GC resulted in improved pulmonary compliance, narrowed septal walls, 
and thinning of pulmonary interstitium in rats with Nitrofen-induced CDH and a 
combination of GC and thyrotropin releasing hormone enhanced these effects.13,14 
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Recently, more attention has focused on vitamin A and its active form, retinoic acid (RA). 
Vitamin A plays an important role in lung development.15 The first evidence linking 
retinoids with CDH came from the observation of diaphragmatic defects in pups born to 
vitamin A-deficient dams as early as the mid 1940s.16 Studies of retinoid receptor double 
null-mutant mice, lacking both the α and β subunits of retinoic acid receptors (RARs), 
have demonstrated that some offspring have a diaphragmatic defect similar to that 
observed in human CDH.17,18 Moreover, co-administration of vitamin A and Nitrofen 
reduces the incidence of CDH in rats by 15 to 30%.19,20 These experimental observations 
suggest that abnormalities within the retinoid signaling pathway may contribute to the 
etiology of CDH, at least in rodent models. To date only one study suggests a 
relationship between RA and CDH in humans. Importantly, enzymes involved in 
degradation of RA, such as RALDH-2, are localized on chromosome 15. 
 
The actions of glucocorticoids, thyroid hormone, and retinoic acid are mediated through 
their specific nuclear receptors and the associated expression levels of the receptors 
form indications for the cellular responsiveness towards certain ligands.21 For this reason 
we examined the expression of these receptors during human lung development 
(chapter 2). Expressions of the glucocorticoid receptor (GR) α, thyroid hormone receptor 
(TR) α and β, retinoic acid receptors (RARs), and retinoid X receptors (RXRs) were 
detected as early as the pseudoglandular stage of lung development. GRα was 
ubiquitously expressed in both epithelium and mesenchyme, albeit more pronounced in 
epithelium. While TRα was expressed in both epithelium and mesenchyme, TRβ was 
detected predominantly in the pulmonary epithelium. Furthermore, the expression 
patterns of these receptors were evaluated in lungs of CDH patients and hypoplastic 
lungs resulting from other causes (chapter 3). No differences in timing and localization of 
these receptors were observed between normal and hypoplastic lungs. Comparable 
findings were demonstrated in lungs of control and Nitrofen-induced CDH rats. Based on 
the information from experimental studies, which demonstrated the potential benefit of 
antenatal GC and vitamin A to promote lung growth and maturation in an animal model 
of CDH, our results indicate that the human CDH lung as well has the potential for a 
similar response to pharmacological modulation. A planned GC study in human prenatal 
CDH cases failed completely because it appeared not possible to include patients in and 
many centers were refused Institutional Board Review approval. 
 
As recommended by the American National Institutes of Health, the use of antenatal GC 
for CDH was adopted for all fetuses between 24 to 34 weeks of gestation at risk of 
preterm delivery.22 However, a caution was raised about the use of this therapy in CDH, 
in view of the paucity of human data, the risks of repetitive antenatal steroid 
administration, and lack of information on dosage and timing. Recent data from a 
randomized trial and cohort study performed by the CDH Study Group showed no 
significant benefit of late prenatal GC in fetuses with CDH and therefore its use is not 
recommended beyond 34 weeks of pregnancy.10 Current interest has turned towards 
retinoic acid since there is strong evidence that the retinoid signaling pathway is involved 
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in the Nitrofen-induced CDH model.23,24 Such evidence is still lacking in human CDH and 
it remains unclear whether retinoids can reduce the severity of pulmonary hypoplasia. 
Aimed at elucidating the potential link between retinoids and human CDH, an 
international multicenter study on retinoids level in plasma from infants with CDH and 
their mothers is ongoing. Further investigations are required in order to assess the real 
potential and/or possible teratogenic risk of vitamin A during the prenatal period.   
 
Moreover, identification of low vitamin A status in mothers who will deliver a child with 
CDH is hampered by the low incidence of CDH (1:3000). While major population based 
studies might solve this problem, we could be confronted with a wide variability between 
countries and populations. 
 
 
PULMONARY VASCULATURE AND AIRWAY BRANCHING MORPHOGENESIS 
From the first morphological sign of lung development, a vascular network surrounds the 
emerging lung buds and expands by formation of new capillaries from preexisting 
vessels as the lung buds grow into the surrounding mesenchyme.25 This angiogenesis 
process is mainly driven by hypoxia. Vascular endothelial growth factor (VEGF) appears 
to be one of the most potent hypoxia-dependent angiogenic growth factors especially 
during lung development.26 VEGF signaling is mediated via its receptors, VEGFR-1 
(Flt-1), VEGFR-2 (Flk-1), and VEGFR-3 (Flt-4). Expression of VEGFR-1 and VEGFR-2 is 
principally in the vascular endothelium, whereas VEGFR-3 is mainly expressed in 
lymphatic endothelium.27 Among these three receptors, VEGFR-2 plays an important role 
in angiogenesis and is one of the earliest molecular indicators of the endothelial cell 
precursor.28,29 VEGF mRNA expression is regulated through hypoxia inducible factor 
(HIF), which in turn is controlled at the protein level by von Hippel-Lindau protein (VHL).30  
 
In the human lung, VEGF and its receptors are localized primarily in airway epithelium 
and vascular endothelium respectively. Epithelial-endothelial interactions during lung 
development are essential for the establishment of a functional blood-gas interface. 
Localization of the VEGF protein in the basement membrane of airway epithelium may 
be important for directing capillary development in the human lung through its paracrine 
effects on endothelial cells. Various studies have provided evidence that the developing 
pulmonary vasculature has an important regulatory role in airway branching 
morphogenesis.31-34 Precise spatial expression and temporal activation of VEGF is 
required for vascular patterning during lung morphogenesis. Fetal lambs showed a three-
fold increase in VEGF expression before birth, despite a strong expression of VEGF 
protein in the lung during early and mid-gestation.35 Our study in human lungs of different 
developmental stages demonstrated comparable expression patterns of VEGF mRNA 
during development. Moreover, mRNA expression of HIF-2α, a potent activator of VEGF, 
also increased with advancing gestation. Our data support the role of the VEGF signaling 
cascade in primitive vascular network formation as well as in preparing the fetal lung for 
the extra uterine environment in the final phase of gestation. 
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There is evidence for morphological abnormalities of the lung vasculature in CDH 
patients.36,37 Hypoplastic lungs with abnormal, thick-walled pulmonary arteries and a 
contracted pulmonary microvascular bed may cause pulmonary hypertension in the 
newborn.38 Similar abnormalities in the pulmonary vessels as in CDH patients have been 
observed in the Nitrofen-induced CDH rat model.39 Immunohistochemistry revealed lower 
VEGF expression in lungs of CDH rats.40 However, contrasting results have been 
reported for the human CDH lungs.41 These were found to show altered expression of 
other angiogenesis-related factors – i.e. increased expression of VHL and decreased 
expression of HIF-1α – compared with age-match control lungs.42 Despite some 
controversial results, these data suggest a role for the VEGF signaling pathway in normal 
and abnormal pulmonary angiogenesis, especially in CDH patients. To date no 
experimental approaches to alter VEGF expression in models of CDH have been 
published as precursors for human studies. Some clinics apply inspiration of the mother 
with 100% oxygen to predict the postnatal vascular reactivity of the pulmonary 
circulation. So far the results are inconclusive, as more subjects are needed to evaluate 
the relative value of these observations. 
 
Prenatal evaluation of echo Doppler flow pattern of the contralateral lung during prenatal 
ultrasound has never resulted in values predicting postnatal vasodilatory capacity of the 
pulmonary vasculature. 
 
 
ROLE OF OXYGEN IN PULMONARY DEVELOPMENT 
Normal pulmonary development takes place in the relatively hypoxic environment in 
utero. Hypoxia is one of the most important factors that drive pulmonary development in 
the embryo. Hypoxia-induced VEGF expression is mediated by molecular oxygen 
sensors, the hypoxia-inducible factors (HIF). Van Tuyl et al. demonstrated that a 
relatively hypoxic environment (3% oxygen) stimulates pulmonary vasculature and 
epithelial branching morphogenesis at least in mouse lungs in vitro.32 In this thesis 
(chapter 5), we demonstrate that a low oxygen environment (1.5% oxygen) stimulates 
VEGF mRNA expression in human lung explants in vitro; no significant changes in 
mRNA expressions of VEGFR-2, HIF-2α, and HIF-3α were observed. We must be 
aware, however, that HIF expression is mainly regulated at the posttranscriptional level, 
and hence further investigation at the protein level is needed for better understanding of 
the role of HIFs in the lung under hypoxic conditions. The use of 100% oxygen during 
artificial ventilation postnatally may have a serious impact on expression of ‘hypoxia’ 
dependent transcription factors and a potentially negative effect on pulmonary vascular 
growth. 
 
Although upregulation of potent angiogenic factors such as VEGF has been 
demonstrated in hypoxic lung cultures, more research is required to prove that an 
increase in VEGF (indirectly) induces airway branching morphogenesis. Extrinsic factors 
such as a hypoxic environment may use the VEGF signaling pathway either directly or 
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through other mediators, to produce an angiogenic effect, which in turn promotes 
pulmonary vascular development. It will not be easy to identify the key molecule in this 
highly orchestrated process during pulmonary development, which is not only regulated 
by VEGF.  
 
This knowledge could be crucial in the care of premature babies. Their lungs normally 
should have developed for a longer period in the relatively hypoxic environment of the 
uterus. Hyperoxic exposure dramatically decreases lung VEGF mRNA expression. 
Blocking of VEGF or inhibition of its receptor, VEGFR-2, during fetal lung development 
results in inhibition of angiogenesis and alveolar hypoplasia, producing pathologic 
features resembling bronchopulmonary dysplasia.43,44 The effect of hyperoxia on 
postnatal pulmonary development in CDH cannot easily be investigated. In clinical 
conditions high inspiratory oxygen fractions are needed with a potential negative effect 
on the pulmonary vasculature. The high incidence of BPD in term born CDH patients 
might reflect this negative effect on the pulmonary vasculature. 
 
 
CONCLUDING REMARKS 
Although extensive research efforts have attempted to elucidate the etiology of CDH and 
associated pulmonary hypertension, many issues remain to be clarified. The use of 
different animal models and materials from human CDH patients revealed confusing and 
sometimes contradicting data. We need to interpret these results and implicate these in 
our clinical practice. Full understanding of the pathophysiology of this disease and of the 
factors that contribute to lung injury will eventually guide the prenatal, perinatal, and 
postnatal management of patients with CDH. Most of the current treatment strategies are 
based on data from animal studies. However, treatment modalities should be further 
studied in properly designed randomized controlled trials, if feasible. International 
collaboration of the CDH Study Group provides important data in this respect, for 
example on the use of prenatal corticosteroids after prenatal diagnosis.10 Beneficial 
effects of pharmacological modulation, especially vitamin A, have been reported in the 
Nitrofen-induced rat model19,20 but the exact mechanisms behind these effects remain 
unknown. The large number of suggested interventions demonstrates that we still have 
not found the optimal solution to improve lung growth or to manage the hypoplastic lung 
and pulmonary hypertension in CDH. 
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SUMMARY 
Congenital diaphragmatic hernia (CDH) is a congenital anomaly with an incidence of one 
in 2,000 to 3,000 live births. The pathophysiology is a mixture of pulmonary vascular and 
pulmonary alveolar abnormalities. Pulmonary hypoplasia and persistent pulmonary 
hypertension are the primary causes of morbidity and mortality in infants with congenital 
diaphragmatic hernia. An extensive volume of work has been performed by a multitude 
of investigators in an attempt to explain the origins of CDH and associated pulmonary 
hyperplasia and hypertension. Nevertheless, to date our understanding of the 
pathophysiology of this disease is still incomplete. However, these studies have yielded 
important insights into mediators and mechanisms of normal lung and diaphragmatic 
growth and development. In addition, some of these investigations have suggested new 
opportunities for intervention. Apart from advances in postnatal management, there have 
been attempts at prenatal intervention aimed at either repairing the defect or enhancing 
lung growth prior to birth.  
 
Chapter 1 describes clinical features of CDH and discusses the variety of current 
treatment strategies as well as the possibilities of prenatal modulations to promote lung 
growth and maturation. Finally it presents the aims of the reported studies. 
 
Chapter 2 describes expression patterns of nuclear hormone receptors in a series of 
normal human fetal lungs from 13.5 weeks of gestation till term. Glucocorticoids, thyroid 
hormone, and vitamin A have been described to influence prenatal lung growth. The 
actions of these ligands are mediated through activation of their receptors, and the level 
of nuclear receptor expression determines cell sensitivities to certain hormones. The 
presence of these receptors in human lung has been documented; however, the 
ontogeny of their expressions has not been shown systematically. The expressions of 
glucocorticoid receptor (GR) α, thyroid hormone receptor (TR) α and β, retinoic acid 
receptor (RAR) α, β, γ, and retinoid X receptor (RXR) α, β, γ were evaluated by 
quantitative PCR and immunohistochemical studies.  
 
As early as 13.5 week of gestation or pseudoglandular stage of lung development, 
mRNA and protein expression of all receptors were detected in human lungs. These 
findings indicate that, as far as receptors are concerned, human fetal lung has the 
potential to respond to glucocorticoids, thyroid hormone, and retinoic acid as early as in 
the pseudoglandular stage, which implies a potential for therapeutic or toxic effects by 
exogenous ligands. 
 
These results in normal human lungs were used as baseline data for the study in 
chapter 3 in which expression patterns of these receptors were evaluate in lungs of 
human CDH cases. The mRNA expression of these receptors was analyzed in 5 CDH 
cases, and immunohistochemistry was performed in 18 CDH cases and 20 cases of 
pulmonary hypoplasia from other causes. As a series of supportive experiments, we 
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examined expression patterns of these receptors in lungs of controls and Nitrofen-
induced CDH rats. 
 
Immunohistochemistry (human and rat) and in situ hybridization (rat) demonstrated no 
overt difference between CDH, hypoplastic, and control lungs, neither in the localization 
nor the timing of the first expression of all analyzed receptors. The mRNA expression of 
each receptor was detected in all human CDH lungs by quantitative PCR. These results 
suggest that the hypoplastic lungs of fetuses or newborns with CDH are potentially as 
responsive to glucocorticoids, thyroid hormone, and retinoic acid as the lungs of normal 
children. Recently, vitamin A has been shown to lower the incidence of CDH in the 
Nitrofen-induced CDH rat model; our results imply a possibility of similar benefit in 
human CDH cases. 
 
In chapter 4 the expressions of various angiogenesis-related factors were evaluated in a 
series of normal human lungs from 13.5 weeks of gestation onwards till term. Hypoxia-
inducible factors (HIF) appear to be key molecules for angiogenesis. However, 
documentation of qualitative and quantitative expression of HIFs in normal human fetal 
lung development was limited. For this reason we evaluated expressions of HIF-1α, HIF-
2α, and HIF-3α along with von Hippel-Lindau protein (VHL), vascular endothelial growth 
factor A (VEGF-A) and its receptor, VEGFR-2 by quantitative PCR. Both HIF-2α and 
VEGF-A mRNA expression showed increasing trend during gestation. Furthermore, 
localization of HIF-1α and HIF-2α was evaluated by immunohistochemistry and this 
revealed that while HIF-1α is expressed in epithelial cells only, HIF-2α is expressed in 
both epithelial and mesenchymal cells. 
 
These findings support the role of the VHL-HIF-VEGF pathway in pulmonary vascular 
development and airway branching morphogenesis in the human fetal lung. 
 
Chapter 5 describes the effects of low oxygen environment on expressions of HIFs in 
human lung in vitro. Human lung explants cultured at 1.5% oxygen were used to 
replicate physiologic conditions during normal fetal lung development. VEGF-A mRNA 
expression is significantly upregulated in explants cultures at 1.5% oxygen. Although 
slight increases in HIF-2α and HIF-3α mRNA expression were observed, the differences 
are not significant. These data suggest that the expression of VEGF-A – and possibly 
HIF-2α and HIF-3α – is regulated by hypoxia in the developing human lung. Moreover 
the experiments in this chapter demonstrate that human fetal lung culture is a valuable 
model to unravel the mechanisms of factors that are known to modulate fetal lung 
development, such as retinoic acid and hormones. 
 
In chapter 6 we investigate cell proliferation and apoptotic related protein in series of 
normal fetal lungs and human CDH lungs during development. Proliferating cells were 
observed in both epithelial and mesenchymal cells. Normal organogenesis requires an 
optimal balance between cell proliferation, cell differentiation, and cell death. The role of 
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apoptosis in pulmonary airway and vascular development was recently described. 
However, further investigation is needed to elucidate the mechanisms involved in 
programmed cell death in pulmonary epithelial and vascular remodeling; we may then 
gain better understanding of the pathophysiology of abnormal lung development as in 
cases of CDH.  
 
Chapter 7 provides a general discussion on pharmacological modulations of fetal lung 
growth, pulmonary vasculature and airway branching morphogenesis; and the role of 
oxygen on pulmonary development.  
 
In conclusion, CDH remains a major challenge to neonatologists and pediatric surgeons. 
In view of the vast variety of clinical features, treatment strategies should be adapted to 
the individual patient. Although many treatment modalities are used in CDH, most of 
them are based on information from animal experiments. The obstacles to obtain human 
data are due to the relatively low incidence of CDH and lack of good international 
collaboration. Only by establishing networks of centers in which enough infants with CDH 
are managed will we be able to conduct appropriately sized randomized trials that can 
contribute to solving some of the crucial dilemmas of the management of these infants 
and can shed light onto their long-term outcome. 
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SAMENVATTING 
Congenitale hernia diafragmatica (CHD) is een aangeboren afwijking die voorkomt bij 
één op de 2000 tot 3000 pasgeborenen. De fysieke uitingen hiervan vormen een 
combinatie van aandoeningen aan de longvaten en de longalveolen. Longhypoplasie en 
persisterende pulmonale hypertensie zijn de belangrijkste oorzaken van de morbiditeit en 
mortaliteit bij kinderen met deze afwijking. Alhoewel er al veel energie en menskracht is 
gestoken in het zoeken naar de oorsprong van CHD en de samengaande 
longhyperplasie en -hypertensie, is het beeld dat wij ervan hebben nog steeds 
incompleet. Niettemin hebben al die onderzoeken waardevol inzicht opgeleverd in de 
mediatoren en mechanismen van de normale groei en ontwikkeling van de longen en het 
middenrif. Tevens zijn er suggesties voor nieuwe interventiemogelijkheden uit 
voortgekomen. Er is niet alleen vooruitgang geboekt in de aanpak vlak na de geboorte; 
ook is er gewerkt aan prenatale interventie, enerzijds gericht op herstel van het 
middenrifdefect, anderzijds op het bevorderen van de longgroei voor de geboorte.  
 
Hoofdstuk 1 beschrijft de klinische kenmerken van CHD en gaat in op de diverse 
beschikbare behandelingsmethoden en de mogelijkheden van prenatale modulatie om 
de groei en rijping van de longen te bevorderen. Het hoofdstuk sluit af met de 
doelstellingen van de onderzoeken die in dit proefschrift worden gepresenteerd. 
 
Hoofdstuk 2 beschrijft de expressiepatronen van nucleaire hormoonreceptoren in een 
reeks normale longpreparaten van menselijke foetussen vanaf 13,5 weken tot voldragen 
zwangerschap. Van glucocorticoïden, schildklierhormoon en vitamine A is aangetoond 
dat ze de prenatale longgroei beïnvloeden. Deze bindingseiwitten komen in werking als 
hun receptoren worden geactiveerd, en het expressieniveau van de nucleaire receptoren 
bepaalt in hoeverre cellen gevoelig zijn voor bepaalde hormonen. Er is aangetoond dat 
deze receptoren voorkomen in de longen van de mens; de ontwikkeling van hun 
expressies is echter nog niet systematisch onderzocht. De expressies van de 
glucocorticoïdreceptor (GR) α, schildklierhormoonreceptor (TR) α en β, de 
retinoïnezuurreceptor (RAR) α, β, γ, en retinoïnezuurreceptor-X (RXR)  α, β, γ werden 
geëvalueerd met behulp van kwantitatieve PCR en immunohistochemisch onderzoek.  
 
Al bij 13,5 week zwangerschap, of de pseudoglandulaire fase van de longontwikkeling, 
vonden we mRNA- en eiwitexpressie van alle receptoren in deze longpreparaten van 
menselijk foetussen. Onze bevindingen wijzen er op dat – wat betreft de receptoren – de 
longen van ongeboren kinderen al in de pseudoglandulaire fase in staat zijn te reageren 
op glucocorticoïden, schildklierhormoon en retinoïnezuurreceptor. Dit geeft aan dat 
exogene bindingseiwitten wellicht therapeutisch of toxisch effect kunnen hebben. 
 
Wat we hadden gevonden voor de normale longontwikkeling bij de mens diende als 
basisgegevens voor het onderzoek dat in Hoofdstuk 3 is beschreven. Nu werden de 
expressiepatronen van deze receptoren bekeken in longmateriaal van kinderen met 
CHD. In vijf gevallen werd de mRNA-expressie van deze receptoren geanalyseerd, en in 
Chapter 8 
 98 
18 gevallen werd immunohistochemisch onderzoek gedaan; dit laatste werd tevens 
gedaan voor 20 gevallen van longhypoplasie door andere oorzaken. Bij wijze van 
ondersteunend onderzoek hebben we ook de expressiepatronen van deze receptoren 
onderzocht bij kinderen uit een controlegroep en bij ratten met CHD geïnduceerd door 
Nitrofen. 
 
Immunohistochemisch onderzoek (mens en rat) en in situ hybridisatie (rat) toonden voor 
alle geanalyseerde receptoren geen opmerkelijke verschillen tussen de longen in geval 
van CHD, van hypoplasie, en van de controlegroep, noch in de lokalisatie, noch in het 
tijdstip waarop de expressie het eerst zichtbaar was. De mRNA-expressie van elke 
receptor werd met behulp van kwantitatieve PCR aangetoond in alle longmateriaal van 
kinderen met CHD. Deze resultaten geven aan dat de hypoplastische longen van 
foetussen of pasgeborenen met CHD potentieel net zo kunnen reageren op 
glucocorticoïden, schildklierhormoon en retinoïnezuurreceptor als de longen van normale 
kinderen. Onlangs heeft men aangetoond dat vitamine A leidt tot lagere incidentie van 
CHD in het Nitrofen-rattenmodel; onze bevindingen impliceren dat een zelfde gunstig 
resultaat kan worden bereikt bij kinderen met CHD. 
 
In Hoofdstuk 4 werd de expressie onderzocht van diverse angiogenese-gerelateerde 
factoren in een serie normale menselijke longen vanaf 13,5 week tot aan het eind van de 
zwangerschap. Hypoxie-induceerbare factors (HIF’s) bleken de sleutelmoleculen te zijn 
voor de angiogenese. De kwalitatieve en kwantitatieve expressie van HIF’s in de 
normale longontwikkeling bij menselijke foetussen is echter nog maar beperkt 
gedocumenteerd. Daarom hebben we met behulp van kwantitatieve PCR de expressie 
van HIF-1α, HIF-2α, en HIF-3α geëvalueerd, alsmede die van Von Hippel-Lindau 
proteïne (VHL), vasculaire endotheel groeifactor A (VEGF-A) en de receptor ervan, 
VEGFR-2. Zowel de expressie van HIF-2α als die van VEGF-A mRNA vertoonden een 
stijgende trend over de zwangerschap. Vervolgens keken we met behulp van 
immunohistochemisch onderzoek naar de lokalisatie van HIF-1α en HIF-2α. Het bleek 
dat HIF-1α alleen maar in epitheelcellen tot uitdrukking kwam, terwijl HIF-2α zowel in 
epitheelcellen als in mesenchymale cellen te zien was. 
 
Deze bevindingen ondersteunen de theorie dat de VHL-HIF-VEGF pathway een rol 
speelt bij de ontwikkeling van de longvaten en bij de morfogenese van de vertakking van 
de luchtwegen in de menselijk foetale long. 
 
Hoofdstuk 5 beschrijft de effecten van laag zuurstofgehalte van de omgeving op de 
expressie van HIF’s in de menselijke long in vitro. Explantaten van menselijke longen 
gekweekt in 1,5% zuurstof dienden om de fysiologische omstandigheden tijdens normale 
foetale longontwikkeling te repliceren. De VEGF-A mRNA-expressie was significant 
verhoogd in deze explantaten. Lichte verhogingen werden waargenomen in de expressie 
van HIF-2α en HIF-3α mRNA, maar de verschillen zijn niet significant. Deze bevindingen 
suggereren dat de expressie van VEGF-A – en mogelijk HIF-2α and HIF-3α – wordt 
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gereguleerd door hypoxie in de zich ontwikkelende menselijk long. Bovendien tonen de 
experimenten in dit hoofdstuk aan dat longkweek van menselijke foetussen een 
waardevol model vormt voor het ontrafelen van de werkingsmechanismen van factoren 
waarvan we weten dat ze de foetale longontwikkeling moduleren, zoals 
retinoïnezuurreceptor en hormonen. 
 
In Hoofdstuk 6 onderzochten we de celproliferatie and apoptose-gerelateerde proteïne 
in series longpreparaten van normale foetussen en van kinderen met CHD tijdens de 
ontwikkeling. We zagen proliferatie van zowel epitheelcellen als mesenchymale cellen. 
De normale organogenese is gestoeld op een optimale balans tussen celproliferatie, 
celdifferentie, en celdood. De rol van apoptose bij de ontwikkeling van de luchtwegen en 
bloedvaten in de longen werd onlangs nog beschreven. Er is echter nader onderzoek 
nodig om de mechanismen te achterhalen die betrokken zijn bij de geprogrammeerde 
celdood die zich voordoet bij de remodeling van longepitheel en -vaten; dit zou ons dan 
een beter begrip geven van de fysieke uitingen van abnormale longontwikkeling zoals in 
gevallen van CHD.  
 
Hoofdstuk 7 brengt een algemene discussie betreffende farmacologische modulering 
van foetale longgroei, het vaatstelsel en de morfogenese van de vertakking van de 
luchtwegen in de longen, en de rol van zuurstof bij de longontwikkeling.  
 
De conclusie luidt dat congenitale hernia diafragmatica nog steeds een belangrijke 
uitdaging vormt voor neonatologen en kinderchirurgen. Aangezien de klinische 
kenmerken sterk uiteenlopen is het zaak om de te volgen behandelingsstrategie aan te 
passen aan de individuele patiënt. Er zijn vele methoden om de behandeling van CHD 
aan te pakken, maar de meeste daarvan zijn gebaseerd op informatie verkregen uit 
dierexperimenten. Gegevensverzameling uit onderzoek bij kinderen wordt belemmerd 
door de relatief geringe incidentie van CHD en het gebrek aan goede internationale 
samenwerking. Alleen als we netwerken vormen van medische centra met voldoende 
aantallen kinderen met CHD kunnen we gerandomiseerde trials van voldoende omvang 
opzetten. Die kunnen dan bijdragen aan het zoeken naar een oplossing voor bepaalde 
cruciale dilemma’s bij de behandeling van die kinderen, en kunnen licht werpen op wat 
deze kinderen op de lange termijn te wachten staat. 
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